[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 234
1. Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD: Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res; 2006 Nov 15;12(22):6791-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: A mouse Nf1:p53 malignant peripheral nerve sheath tumor (MPNST) cell line expressing dnFGFR was generated by transfection.
  • RESULTS: MPNST 61E4 cells expressing dnFGFR grew less well than parental control cells. bG47Delta-dnFGFR showed enhanced killing of both tumor (human U87 glioma and F5 malignant meningioma cells and murine MPNST 61E4 and 37-3-18-4 cells) and proliferating endothelial cells (human umbilical vascular endothelial cell and Py-4-1) in vitro compared with the control vector bG47Delta-empty without inhibiting viral replication.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121900.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS032677
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Receptors, Fibroblast Growth Factor; 0 / Recombinant Proteins
  •  go-up   go-down


2. Ochi M, Igase M, Nagai A, Nakamura S, Nagai T, Kawajiri M, Nakura J, Kohara K, Miki T: [A case of Werner syndrome with chromosomal abnormality]. Nihon Ronen Igakkai Zasshi; 2006 Sep;43(5):639-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of Werner syndrome with chromosomal abnormality].
  • She was referred to our hospital in November 2002 because of anemia, thyroid tumor and meningioma including DM.
  • Typical physical features led to the final diagnosis of Werner's syndrome.
  • She had a thyroidectomy because both lobes of the thyroid gland were enlarged and caused hoarseness, In addition, it is common knowledge that the goiter could become malignant.
  • We need to follow her carefully because she might be vulnerable to malignant disease, including leukemia and malignant meningioma.

  • Genetic Alliance. consumer health - Werner's syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17073296.001).
  • [ISSN] 0300-9173
  • [Journal-full-title] Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics
  • [ISO-abbreviation] Nihon Ronen Igakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Sanai N, Sughrue ME, Shangari G, Chung K, Berger MS, McDermott MW: Risk profile associated with convexity meningioma resection in the modern neurosurgical era. J Neurosurg; 2010 May;112(5):913-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk profile associated with convexity meningioma resection in the modern neurosurgical era.
  • OBJECT: Although meningiomas are commonly found along the supratentorial convexity, the risk profile associated with this subset of lesions in the modern neurosurgical era is unknown.
  • METHODS: The authors retrospectively reviewed the clinical course of patients with supratentorial convexity meningiomas treated during the past 10 years.
  • Patients with multiple meningiomas, hemangiopericytomas, malignant meningiomas, or tumor-prone syndromes were excluded from analysis.
  • RESULTS: Between 1997 and 2007, 141 consecutive patients (median age 48 years, range 18-95 years) underwent resection of a supratentorial convexity meningioma.
  • CONCLUSIONS: With the conservative recommendations for surgery for asymptomatic meningiomas and the advent of radiosurgery during the past 10 years, microsurgically treated convexity meningiomas are now typically large in size.
  • The authors' findings provide a defined risk profile associated with the resection of supratentorial convexity meningiomas in the modern neurosurgical era.
  • [MeSH-major] Meningioma / pathology. Meningioma / surgery. Neurosurgical Procedures / methods. Radiosurgery / methods. Supratentorial Neoplasms / pathology. Supratentorial Neoplasms / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645533.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Sugo N, Yokota K, Kondo K, Harada N, Aoki Y, Miyazaki C, Nemoto M, Kano T, Ohishi H, Seiki Y: Early dynamic 201Tl SPECT in the evaluation of brain tumours. Nucl Med Commun; 2006 Feb;27(2):143-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In static SPECT, there was no significant difference between the STI of malignant tumours (glioblastoma and anaplastic astrocytoma) and that of benign tumours (low-grade glioma, meningioma, pituitary adenoma, neurinoma and haemangioblastoma) (3.7+/-1.5, 5.0+/-3.5, respectively).
  • On dynamic SPECT, DTI increased markedly over 15 min for malignant tumours.
  • The slope of the linear functions calculated from the DTRs was much higher in the malignant tumour group than in the benign tumour group (P<0.001).
  • CONCLUSIONS: We suggest that the performance of 201Tl dynamic SPECT for 15 min is useful for distinguishing malignant brain tumours from benign brain tumours and reduces the examination stress of patients.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. THALLOUS CHLORIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404227.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 7791-12-0 / thallium chloride; AD84R52XLF / Thallium
  •  go-up   go-down


5. Bledsoe JM, Link MJ, Stafford SL, Park PJ, Pollock BE: Radiosurgery for large-volume (&gt; 10 cm3) benign meningiomas. J Neurosurg; 2010 May;112(5):951-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosurgery for large-volume (> 10 cm3) benign meningiomas.
  • OBJECT: Stereotactic radiosurgery (SRS) has proven to be a safe and effective treatment for many patients with intracranial meningiomas.
  • Nevertheless, the morbidity associated with radiosurgery of larger meningiomas is poorly understood.
  • METHODS: The authors performed a retrospective review of 116 patients who underwent SRS for meningiomas (WHO Grade I) > 10 cm3 between 1990 and 2007, with a minimum follow-up of 12 months.
  • Patients with atypical or malignant meningiomas and those who received prior radiotherapy were excluded.
  • CONCLUSIONS: The morbidity associated with SRS for patients with benign meningiomas > 10 cm(3) is greater for supratentorial tumors compared with skull base tumors.
  • Whereas radiosurgery is relatively safe for patients with large-volume skull base meningiomas, resection should remain the primary disease management for the majority of patients with large-volume supratentorial meningiomas.
  • [MeSH-major] Meningioma / pathology. Meningioma / surgery. Radiosurgery / instrumentation. Skull Base Neoplasms / pathology. Skull Base Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2010 Dec;113(6):1335-6; author reply 1336-7 [20887089.001]
  • (PMID = 19764829.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Puduvalli VK, Li JT, Chen L, McCutcheon IE: Induction of apoptosis in primary meningioma cultures by fenretinide. Cancer Res; 2005 Feb 15;65(4):1547-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of apoptosis in primary meningioma cultures by fenretinide.
  • Due to its ease of administration, long-term tolerability, and low incidence of long-term side effects, we explored its potential as a therapeutic agent against meningiomas by examining its efficacy in vitro against such cells in primary culture.
  • Cells, cultured from freshly resected benign, atypical, or malignant meningiomas, were exposed to fenretinide (10 mumol/L).
  • Fenretinide induced apoptosis in the three grades of meningioma primary cells tested, as shown by the appearance of a sub-G(1) fraction in flow cytometric analysis and by the detection of poly-adenosyl ribonucleotidyl phosphorylase cleavage indicating caspase activation.
  • IGF-I-induced proliferation in the meningioma cells was abolished by fenretinide.
  • We conclude that fenretinide induces apoptosis in all three histologic subtypes of meningioma and exerts diverse cellular effects, including DR5 up-regulation, modulation of retinoid receptor levels, and inhibition of IGF-I-induced proliferation.
  • These results provide preliminary evidence that fenretinide has activity against meningiomas and suggest that further studies are warranted to explore its potential as a therapeutic agent against meningiomas.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Fenretinide / pharmacology. Meningioma / drug therapy

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735044.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Retinoic Acid; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / Retinoid X Receptor alpha; 0 / TNFRSF10B protein, human; 0 / retinoic acid receptor alpha; 0 / retinoic acid receptor gamma; 187EJ7QEXL / Fenretinide; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.7.7.8 / Polyribonucleotide Nucleotidyltransferase
  •  go-up   go-down


7. Torp SH, Lindboe CF, Grønberg BH, Lydersen S, Sundstrøm S: Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas. Clin Neuropathol; 2005 Jul-Aug;24(4):170-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
  • Even though tumor grade, subtype, and extent of resection are strong prognostic factors in human meningiomas, the growth of this tumor is still unpredictable, and additional prognostic markers are needed.
  • However, the reported prognostic significance of this marker in meningiomas is not fully clarified.
  • The aim of this study was to investigate the prognostic role of MIB-1 proliferation index (PI) in a series of meningiomas comprising 23 benign, 17 atypical, and 9 anaplastic tumors.
  • MIB- 1 PI increased with increasing tumor grade and discriminated significantly benign from atypical and anaplastic meningiomas whereas no difference was found between the latter two grades.
  • In conclusion, MIB-1 PI appears as an important prognostic factor and should be used in combination with traditional histological criteria for malignancy in order to identify meningiomas with increased risk of recurrence.
  • [MeSH-major] Antibodies, Antinuclear / analysis. Antibodies, Monoclonal / analysis. Biomarkers, Tumor / analysis. Ki-67 Antigen / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033133.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / MIB-1 antibody
  •  go-up   go-down


8. Greco JJ, Aiken SA, Berg JM, Monette S, Bergman PJ: Evaluation of intracranial meningioma resection with a surgical aspirator in dogs: 17 cases (1996-2004). J Am Vet Med Assoc; 2006 Aug 1;229(3):394-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of intracranial meningioma resection with a surgical aspirator in dogs: 17 cases (1996-2004).
  • OBJECTIVE: To determine results of intracranial meningioma resection by use of a surgical aspirator and assess prognostic factors associated with intracranial meningiomas in dogs.
  • PROCEDURES: Medical records of dogs that underwent resection of an intracranial meningioma by use of a surgical aspirator were reviewed.
  • Analysis of survival times according to histologic tumor subtypes indicated that the order from most brief to longest was as follows: anaplastic, 0 days; fibroblastic, 10 days; psammomatous, > 313 days; meningothelial, > 523 days; and transitional, 1,254 days.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Use of a surgical aspirator to resect intracranial meningiomas in dogs was associated with longer survival times than those achieved with traditional surgery alone or traditional surgery combined with radiation therapy.
  • Dogs with meningothelial, psammomatous, or transitional intracranial meningioma subtypes appeared to have a better prognosis than dogs with other subtypes of meningioma.
  • [MeSH-major] Dog Diseases / surgery. Meningeal Neoplasms / veterinary. Meningioma / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16881832.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Eom HS, Kim MS, Hur SY, Yoo NJ, Lee SH: Absence of oncogenic AKT1 E17K mutation in prostate, esophageal, laryngeal and urothelial carcinomas, hepatoblastomas, gastrointestinal stromal tumors and malignant meningiomas. Acta Oncol; 2009;48(7):1084-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of oncogenic AKT1 E17K mutation in prostate, esophageal, laryngeal and urothelial carcinomas, hepatoblastomas, gastrointestinal stromal tumors and malignant meningiomas.
  • [MeSH-minor] DNA Mutational Analysis. Esophageal Neoplasms / genetics. Female. Gastrointestinal Stromal Tumors / genetics. Hepatoblastoma / genetics. Humans. Laryngeal Neoplasms / genetics. Male. Meningioma / genetics. Prostatic Neoplasms / genetics. Urologic Neoplasms / genetics

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19353338.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


10. Gogineni VR, Kargiotis O, Klopfenstein JD, Gujrati M, Dinh DH, Rao JS: RNAi-mediated downregulation of radiation-induced MMP-9 leads to apoptosis via activation of ERK and Akt in IOMM-Lee cells. Int J Oncol; 2009 Jan;34(1):209-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients afflicted with meningiomas are most often treated with radiation therapy followed by surgical resection.
  • In this study, we demonstrate that the malignant meningioma cells (IOMM-Lee cells) overexpress MMP-9 at both the mRNA and protein levels after radiation treatment.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2006 Nov 9;25(53):7009-18 [16732316.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8511-9 [16951163.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):789-801 [17363476.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4956-64 [17510426.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1171-80 [17634416.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2307-16 [17657740.001]
  • [Cites] Surg Neurol. 2007 Dec;68(6):610-3; discussion 613-4 [17765959.001]
  • [Cites] J Biol Chem. 2008 Jan 18;283(3):1545-52 [17991734.001]
  • [Cites] Int J Oncol. 2008 Mar;32(3):557-64 [18292932.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1161-9 [12829155.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5967-75 [12955075.001]
  • [Cites] Cancer Gene Ther. 2003 Nov;10(11):823-32 [14605668.001]
  • [Cites] Biol Chem. 2004 Jan;385(1):75-86 [14977049.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):147-57 [15072462.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2B):967-72 [15161051.001]
  • [Cites] Neurotoxicology. 2004 Dec;25(6):915-24 [15474610.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] Ann Surg. 2000 May;231(5):644-54 [10767785.001]
  • [Cites] J Neurooncol. 2000 May;48(1):51-5 [11026697.001]
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):766-71 [11072246.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2744-50 [11289157.001]
  • [Cites] J Neurosurg. 2001 Jun;94(6):978-84 [11409528.001]
  • [Cites] Adv Exp Med Biol. 2000;486:355-9 [11783515.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4932-44 [11733515.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1223-7 [11948136.001]
  • [Cites] Biochem J. 2002 Jul 1;365(Pt 1):31-40 [12071839.001]
  • [Cites] Oncogene. 2002 Aug 15;21(36):5601-8 [12165859.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Neurosurgery. 1987 Apr;20(4):525-8 [3587542.001]
  • [Cites] BMC Cancer. 2002 Dec 3;2:34 [12464160.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Med Phys. 1995 Nov;22(11 Pt 2):1889-97 [8587542.001]
  • [Cites] Pflugers Arch. 1998 Mar;435(4):546-54 [9446703.001]
  • [Cites] J Surg Res. 1999 Jun 15;84(2):162-7 [10357914.001]
  • [Cites] J Appl Toxicol. 2005 Sep-Oct;25(5):374-82 [16013042.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):99-103 [16193379.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6785-93 [16709838.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):73-7 [16292489.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Dec;319(3):991-7 [16801453.001]
  • (PMID = 19082492.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS061835; United States / NINDS NIH HHS / NS / R01 NS057529; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / R01 CA116708-03; United States / NCI NIH HHS / CA / R01 CA095058-04; United States / NINDS NIH HHS / NS / R01 NS057529-02; United States / NINDS NIH HHS / NS / R01 NS061835-01; United States / NCI NIH HHS / CA / CA 75557; United States / NCI NIH HHS / CA / CA116708-03; United States / NCI NIH HHS / CA / CA075557-10; United States / NCI NIH HHS / CA / CA 92393; United States / NINDS NIH HHS / NS / NS061835-01; United States / NCI NIH HHS / CA / CA 95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NINDS NIH HHS / NS / NS057529-02; United States / NCI NIH HHS / CA / CA092393-04; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA 116708; United States / NCI NIH HHS / CA / R01 CA092393-04; United States / NINDS NIH HHS / NS / R01 NS047699-04A2; United States / NINDS NIH HHS / NS / NS047699-04A2; United States / NCI NIH HHS / CA / CA095058-04; United States / NCI NIH HHS / CA / R01 CA075557-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Drug Combinations; 0 / Enzyme Inhibitors; 0 / FAS protein, human; 0 / Laminin; 0 / Matrix Metalloproteinase Inhibitors; 0 / Proteoglycans; 0 / RNA, Small Interfering; 119978-18-6 / matrigel; 9007-34-5 / Collagen; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ NIHMS71812; NLM/ PMC2605673
  •  go-up   go-down


11. Martin-Vaquero P, Da Costa RC, Aeffner F, Oglesbee MJ, Echandi RL: Imaging diagnosis--Hemorrhagic meningioma. Vet Radiol Ultrasound; 2010 Mar-Apr;51(2):165-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging diagnosis--Hemorrhagic meningioma.
  • The histologic diagnosis was anaplastic meningioma with acute hemorrhage.
  • These findings document an unusual appearance of a meningioma in MR images due to intratumoral hemorrhage.
  • [MeSH-major] Dog Diseases / diagnosis. Intracranial Hemorrhages / veterinary. Meningeal Neoplasms / veterinary. Meningioma / veterinary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20402404.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Yonekawa Y: [Operative neurosurgery: personal view and historical backgrounds. (5) Meningioma]. No Shinkei Geka; 2009 Jan;37(1):71-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Operative neurosurgery: personal view and historical backgrounds. (5) Meningioma].
  • The author reports his experience of 410 surgeries of meningiomas on 365 cases during the last 13.5 years, including 51 surgeries on recurrent meningiomas and 8 surgeries with the change of initial approach on the same meningiomas.
  • In the surgical management of meningiomas, following comments are to be emphasized: Appropriate approach and interruption of blood supply are of cardinal importance in surgical management of meningiomas.
  • For the latter purpose, preoperative embolization of feeding arteries is recommended especially in deep seated and large meningiomas more than 3 cm in diameter for carrying out their surgical extirpation fast and radically.
  • Olfactory groove meningiomas, planum sphenoidal meningiomas, tuberculum sellae meningiomas and sphenoid ridge meningiomas are managed with pterional approach.
  • The latter two meningiomas may necessitate selective extradural anterior clinoidectomy SEAC.
  • For the management of large midline meningiomas, combination with interhemispheric approach is necessary to manage pial supply appropriately for the preservation of circulation of the anterior cerebral artery ACA.
  • Extension of the former two meningiomas to the other side can be managed with falcal incision and/or drilling out of the crista galli without performing a bifrontal approach.
  • Reduction of exophthalmos due to sphenoid ridge meningiomas infiltrating Periorbita and extraocular muscles is hardly to be expected even after subtotal removal and extensive decompression of the orbita at the superior and lateral walls in combination with SEAC.
  • Meningiomas in the cavernous sinus should be observed as long as possible in case of no growth, as they remain the same in their size and extension mostly for a long time.
  • Appropriate approaches for meningiomas arising from the incisura tentorii would be either the amygdalohippocampectomy AHE approach namely transSylvian transsulcus circularis approach for their anterior localization or the supracerebellar transtentorial SCTT approach for the posterior localization in the sitting position.
  • Meningiomas of the falcotentorial junction are managed also with this approach but may necessitate combination of the suboccipital transtentorial approach large upper clivus meningiomas can be removed more effectively by paramedian or lateral suboccipital craniotomy via SCTT approach in the sitting position rather than the subtemporal transpetrosal approach.
  • Special mention is made to transvertebralis (dural) ring approach TVRA for the foramen magnum or lower clivus meningiomas, in which the vertebral artery can be mobilized without performing more extensive far lateral approach.
  • Difficulties of management of recurrent parasagittal meningiomas with the location corresponding to the gyrus paracentralis plus supplementary motor area are to be emphasized.
  • Difficulties of management of recurrent meningiomas represented by atypical or anaplastic meningiomas WHO grade II or III which can not be managed only by surgical removal is discussed by presenting some example cases.
  • Biological activity of meningiomas in different location can be quite different in multiple recurrent meningiomas.
  • Meningiomas intractable to irradiation and/or chemotherapy are another challenging topic, being beyond the scope of this paper.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Neurosurgical Procedures / methods

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19175037.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 39
  •  go-up   go-down


13. Maeda H, Shibuya H, Suzuki K, Kuwabara M, Tsukise A, Sato T: A case of anaplastic meningioma in a dog. J Vet Med Sci; 2005 Nov;67(11):1177-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of anaplastic meningioma in a dog.
  • This tumor was diagnosed as anaplastic meningioma, which is rarely observed in dogs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327232.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Vimentin
  •  go-up   go-down


14. Ahmadi SA, Samadi N: Evaluation of argyrophilic nucleolar organizer region staining in predicting the behavior of meningiomas. Ann Saudi Med; 2006 Jan-Feb;26(1):38-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of argyrophilic nucleolar organizer region staining in predicting the behavior of meningiomas.
  • Comparing nonrecurrent, recurrent, atypical and malignant meningiomas we studied the value of the routine applicability of the AgNOR count in the prognostication of this tumor.
  • PATIENTS AND METHODS: Two hundred and thirty-eight meningiomas were reviewed blindly and graded using WHO grading schema.
  • Eighty-one cases were selected and arranged in six groups according to clinical data and grading: 14 benign non-recurrent meningiomas; 14 primary benign recurrent meningiomas and their subsequent benign recurrences; 14 atypical; 11 malignant and 14 spinal meningiomas.
  • There was a significant difference between benign non-recurrenttumors versus benign recurrent (P<0.0001) and atypical or malignant (P<0.0001) tumors.
  • A difference was also noted between the recurring tumors versus malignant ones (P = 0.002) but no significant difference was seen between recurrent and atypical; atypical and malignant; intracranial and intraspinal; and primary of recurring meningiomas with their subsequent recurrences.
  • A mean AgNOR count of <2.3 could separate benign tumors from atypical or malignant meningiomas with 93% specificity; and 93% of tumors with benign histology had no recurrence potential if their mean AgNOR count was less than 1.8.
  • CONCLUSION: This study indicates that in meningioma, the AgNOR count has a good correlation with tumor grading and recurrence, which may aid pathologists and clinicians in predicting tumor behavior.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Nucleolus Organizer Region / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16521873.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


15. Pećina-Slaus N, Nikuseva Martić T, Tomas D, Beros V, Zeljko M, Cupić H: Meningiomas exhibit loss of heterozygosity of the APC gene. J Neurooncol; 2008 Mar;87(1):63-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningiomas exhibit loss of heterozygosity of the APC gene.
  • The molecular mechanisms and candidate genes involved in development of meningiomas still need investigation and elucidation.
  • In the present study 33 meningiomas were analyzed regarding genetic changes of tumor suppressor gene Adenomatous polyposis coli (APC), a component of the wnt signaling.
  • The changes were distributed according to pathohistological grade as follows: 46% of meningothelial meningioma showed LOH; 33% of fibrous; 75% of mixed (transitional); 75% of angiomatous, and one LOH was found in a single case of psammomatous meningioma.
  • None of the LOHs were found in atypical and anaplastic cases.
  • The results of this investigation suggest that genetic changes of APC gene play a role in meningioma formation.
  • [MeSH-major] Genes, APC. Loss of Heterozygosity. Meningeal Neoplasms / genetics. Meningioma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Clin Neuropathol. 2005 Jan-Feb;24(1):8-12 [15696778.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1370-5 [16251967.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22429-33 [16793760.001]
  • [Cites] Histopathology. 2006 Aug;49(2):178-87 [16879395.001]
  • [Cites] Neurosurgery. 2004 Nov;55(5):1163-73 [15509323.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Nat Neurosci. 2003 Nov;6(11):1169-77 [14528308.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Mar;9(3):168-72 [7515658.001]
  • [Cites] J Neurobiol. 2005 Sep 15;64(4):458-75 [16041741.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):163-7 [9504862.001]
  • [Cites] Cancer Cell Int. 2003 Oct 14;3(1):17 [14613514.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Curr Opin Neurobiol. 2000 Jun;10(3):392-9 [10851180.001]
  • [Cites] Neuroscience. 1999;91(2):661-72 [10366023.001]
  • [Cites] Adv Anat Pathol. 2005 Jul;12(4):180-94 [16096380.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Pathology. 2004 Apr;36(2):145-51 [15203750.001]
  • [Cites] Cell. 2000 Mar 3;100(5):525-35 [10721990.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):445-9 [11433413.001]
  • [Cites] Cancer Lett. 2002 Sep 8;183(1):95-101 [12049819.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):249-56 [15540215.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 18066497.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Heros RC: Malignant meningiomas. J Neurosurg; 2010 Aug;113(2):199-200; discussion 200-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant meningiomas.
  • [MeSH-major] Meningeal Neoplasms. Meningioma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Neurosurg. 2010 Aug;113(2):202-9 [20225922.001]
  • (PMID = 20225919.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


17. Paramanathan N, Ooi KG, Reeves D, Wilcsek GA: Synchronous radiation-induced orbital meningioma and multiple cavernomas. Clin Exp Ophthalmol; 2010 May;38(4):414-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous radiation-induced orbital meningioma and multiple cavernomas.
  • We present the first reported case of synchronous radiation-induced orbital meningioma and cavernomas of the cerebellum and bilateral basal ganglia, presenting 16 years after ionizing radiation therapy for parietal anaplastic ependymoma, at the age of five.
  • [MeSH-major] Basal Ganglia Diseases / etiology. Cerebellar Neoplasms / etiology. Hemangioma, Cavernous / etiology. Meningioma / etiology. Neoplasms, Multiple Primary / etiology. Neoplasms, Radiation-Induced. Orbital Neoplasms / etiology

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Radiation induced meningioma.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20491803.001).
  • [ISSN] 1442-9071
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


18. Giussani C, Pirillo D, Roux FE: Mirror of the soul: a cortical stimulation study on recognition of facial emotions. J Neurosurg; 2010 Mar;112(3):520-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: After a preoperative neuropsychological evaluation, 18 consecutive patients with right hemispheric lesions (5 metastases, 6 high-grade gliomas, 4 low-grade gliomas, 2 arteriovenous malformations, and 1 malignant meningioma) were tested by intraoperative cortical stimulation while performing a facial emotion recognition task along with sensorimotor and visuospatial tasks.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538049.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Payen JF, Faillot T, Audibert G, Vergnes MC, Bosson JL, Lestienne B, Bernard C, Bruder N: [Thromboprophylaxis in neurosurgery and head trauma]. Ann Fr Anesth Reanim; 2005 Aug;24(8):921-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific risk factors in neurosurgery are: a motor deficit, a meningioma or malignant tumour, a large tumour, age over 60 years, surgery lasting more than 4 hours, a chemotherapy.

  • MedlinePlus Health Information. consumer health - Head Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006086.001).
  • [ISSN] 0750-7658
  • [Journal-full-title] Annales françaises d'anesthèsie et de rèanimation
  • [ISO-abbreviation] Ann Fr Anesth Reanim
  • [Language] fre
  • [Publication-type] English Abstract; Guideline; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 34
  •  go-up   go-down


20. Sasayama T, Nishihara M, Tanaka K, Mizukawa K, Ehara K, Kanomata N, Kohmura E: Two metachronous tumors induced by radiation therapy: case report and review of the literature. J Neurooncol; 2008 Jul;88(3):315-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various radiation-induced tumors, including meningioma, glioma, and sarcoma, have been reported; however, metachronous intracranial double tumors induced by radiation therapy are extremely rare.
  • At 24 years old, parasagittal meningioma developed in the left parietal region and was totally removed.
  • The patient underwent stereotactic biopsy, and the tumor was found to be an anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasms, Radiation-Induced / pathology. Neoplasms, Second Primary / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 1992 May 23;304(6838):1343-6 [1611331.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):390-7 [10958546.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):65-73 [10924973.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):161-81 [15674476.001]
  • [Cites] Surg Neurol. 2003 Jul;60(1):60-7; discussion 67 [12865017.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):73-7 [16292489.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):111-5 [9420081.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1002-13 [15200115.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):393-6 [9007876.001]
  • [Cites] Radiat Oncol. 2007 Jan 11;2:5 [17217530.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):143-6 [10729825.001]
  • [Cites] Childs Nerv Syst. 2006 Sep;22(9):1201-7 [16570196.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4091-5 [8508374.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Cancer Causes Control. 1997 Nov;8(6):865-71 [9427429.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):436-45 [2995867.001]
  • [Cites] Neurol Res. 2007 Oct;29(7):723-6 [17553214.001]
  • [Cites] Neurosurgery. 1995 Apr;36(4):685-90 [7596497.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(8):763-70 [9810442.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):564-74 [1885974.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jul;59(7):614-20 [10901233.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] Cancer Lett. 1999 Jan 29;135(2):223-8 [10096432.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):77-82 [2661743.001]
  • [Cites] Neurosurgery. 1996 May;38(5):915-24; discussion 924-5 [8727816.001]
  • (PMID = 18373066.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Johnson MD, Vito F, O'Connell MJ: Mesothelin expression in the leptomeninges and meningiomas. J Histochem Cytochem; 2008 Jun;56(6):579-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelin expression in the leptomeninges and meningiomas.
  • The identity and functions of surface proteins on human leptomeningeal and meningioma cells are incompletely characterized.
  • Sections of 20 normal adult brains with leptomeninges and 49 World Health Organization (WHO) grade I, 21 grade II, and 2 grade III meningiomas were analyzed using an extensively characterized monoclonal antibody to mesothelin and streptavidin-biotin complex immunohistochemistry.
  • Five meningiomas were also evaluated by Western blot.
  • Mesothelin immunoreactivity was detected in the arachnoid in 6 of 20 cases and in 23 of 49 WHO grade I meningiomas.
  • It was also detected in 7 of 21 WHO II tumors and 1 of the 2 anaplastic meningiomas.
  • By Western blot, all five meningiomas exhibited mesothelin precursor protein, including one where notable immunoreactivity was not identified in a formalin-fixed tissue section.
  • These findings suggest that mesothelin is expressed in at least some arachnoid and meningioma cells.
  • Future studies may clarify its role in the development of meningiomas, meningeal seeding of gliomas, and metastases to the leptomeninges.
  • [MeSH-major] Arachnoid / metabolism. Membrane Glycoproteins / biosynthesis. Meningeal Neoplasms / metabolism. Meningioma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1995 Sep 15;270(37):21984-90 [7665620.001]
  • [Cites] Int J Cancer. 1992 Jun 19;51(4):548-54 [1351045.001]
  • [Cites] Lab Invest. 1997 Dec;77(6):601-6 [9426397.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6 [10500211.001]
  • [Cites] Morphologie. 2005 Mar;89(284):22-34 [15943078.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5840-6 [16115924.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] Am J Respir Crit Care Med. 2006 May 15;173(10):1155-60 [16456138.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4225-31 [16857795.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]
  • [Cites] Mol Cancer. 2006;5(1):50 [17067392.001]
  • [Cites] Neuropathology. 2007 Feb;27(1):36-42 [17319281.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1571-5 [17332303.001]
  • [Cites] Thorax. 2007 Jul;62(7):569-76 [17356060.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9055-65 [17909009.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2902-6 [10733593.001]
  • [Cites] Respirology. 2002 Sep;7(3):171-91 [12153683.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):605-9 [12827615.001]
  • [Cites] J Biol Chem. 1994 Jan 14;269(2):805-8 [8288629.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1418-28 [14576474.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9190-8 [14676194.001]
  • [Cites] BMC Cancer. 2004 May 12;4:19 [15140265.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 [15217923.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 [8552591.001]
  • (PMID = 18347077.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  • [Other-IDs] NLM/ PMC2386771
  •  go-up   go-down


22. Grill J, Lamfers ML, van Beusechem VW, van der Valk P, Huisman A, Sminia P, Alemany R, Curiel DT, Vandertop WP, Gerritsen WR, Dirven CM: Oncolytic virotherapy of meningiomas in vitro with replication-competent adenovirus. Neurosurgery; 2005;56(1):146-53; discussion 153-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncolytic virotherapy of meningiomas in vitro with replication-competent adenovirus.
  • OBJECTIVE: To evaluate the efficacy of the conditionally replicating adenovirus (Ad) Ad.d24 for oncolysis of benign and malignant meningiomas.
  • METHODS: Primary meningioma cells and organotypic spheroids were cultured from tumor biopsies of 12 consecutive unselected patients.
  • Four different Ads were constructed and tested on meningioma cells and spheroids: a replication-deficient Ad encoding the luciferase marker gene (Ad.Luc), a replication-competent Ad with complete E1 region (Ad.E1+), a replication-competent Ad encoding the luciferase gene in the E3 region (Ad.E1Luc), and a conditionally replicating Ad with an E1ACR2 deletion (Ad.d24).
  • Their oncolytic activity was compared in primary meningioma cells and spheroids by use of viability and outgrowth assays.
  • RESULTS: Adenoviral penetration into organotypic meningioma spheroids was detected with the replication-competent Ad.E1Luc, whereas infection with the replication-deficient Ad.Luc was limited to the outer layer of the spheroid.
  • Replication of the Ads and oncolysis was demonstrated in primary cell cultures of meningioma cells at high dose, i.e., greater than 50 plaque-forming units per cell.
  • At a lower dose of 5 plaque-forming units per cell, Ad.d24 kills meningioma cells more efficiently than Ad.E1+.
  • Infection of organotypic meningioma spheroids with Ad.d24 resulted in decreased viability and suppression of outgrowth as compared with untreated control spheroids.
  • CONCLUSION: Infection of meningioma cells and spheroids with replication-competent Ads results in efficient oncolysis.
  • The Ad modified to replicate selectively in retinoblast-mutant cells, Ad.d24, seemed to be an efficient oncolytic agent in benign, atypical, and malignant meningiomas.
  • [MeSH-major] Meningioma / therapy. Oncolytic Virotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15617597.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Okamoto H, Li J, Vortmeyer AO, Jaffe H, Lee YS, Gläsker S, Sohn TS, Zeng W, Ikejiri B, Proescholdt MA, Mayer C, Weil RJ, Oldfield EH, Zhuang Z: Comparative proteomic profiles of meningioma subtypes. Cancer Res; 2006 Oct 15;66(20):10199-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative proteomic profiles of meningioma subtypes.
  • Meningiomas are classified into three groups (benign, atypical, and anaplastic) based on morphologic characteristics.
  • Atypical meningiomas, which are WHO grade 2 tumors, and anaplastic meningiomas, which are WHO grade 3 tumors, exhibit an increased risk of recurrence and premature death compared with benign WHO grade 1 tumors.
  • Although atypical and anaplastic meningiomas account for <10% of all of meningiomas, it can be difficult to distinguish them from benign meningiomas by morphologic criteria alone.
  • We used selective tissue microdissection to examine 24 human meningiomas and did two-dimensional gel electrophoresis to determine protein expression patterns.
  • Proteins expressed differentially by meningiomas of each WHO grade were identified and sequenced.
  • Proteomic analysis revealed protein expression patterns unique to WHO grade 1, 2, and 3 meningiomas and identified 24 proteins that distinguish each subtype.
  • Fifteen proteins showed significant changes in expression level between benign and atypical meningiomas, whereas nine distinguished atypical from anaplastic meningiomas.
  • We established differential proteomic profiles that characterize and distinguish meningiomas of increasing grades.
  • The proteins and proteomic profiles enhance understanding of the pathogenesis of meningiomas and have implications for diagnosis, prognosis, and treatment.
  • [MeSH-major] Meningeal Neoplasms / classification. Meningioma / classification

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17047085.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


24. Benesch M, Siegler N, Hoff Kv, Lassay L, Kropshofer G, Müller H, Sommer C, Rutkowski S, Fleischhack G, Urban C: Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study. Anticancer Drugs; 2009 Oct;20(9):794-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nineteen heavily pretreated patients (males, n = 14; females, n = 5; median age at diagnosis 8.5 years; range, 1.4-22 years) were given intrathecal liposomal cytarabine on a compassionate use basis for recurrent refractory medulloblastoma (n = 12), mixed germ cell tumor (n = 2), central nervous system primitive neuroectodermal tumors of the pons (n = 1), anaplastic ependymoma (n = 1), anaplastic oligodendroglioma (n = 1), atypical teratoid rhabdoid tumor (n = 1), or rhabdoid papillary meningioma (n = 1).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617818.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Delayed-Action Preparations; 0 / Liposomes; 04079A1RDZ / Cytarabine
  •  go-up   go-down


25. Schiffer D, Ghimenti C, Fiano V: Absence of histological signs of tumor progression in recurrences of completely resected meningiomas. J Neurooncol; 2005 Jun;73(2):125-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of histological signs of tumor progression in recurrences of completely resected meningiomas.
  • In meningioma recurrences a tumor progression has been proposed on a molecular genetic basis.
  • Seventy-six completely resected recurrent meningiomas have been studied.
  • Most tumors were convexity or parasagittal meningiomas.
  • The greater number of recurrences in atypical and anaplastic tumors depends on their initial higher proliferation capacity.
  • [MeSH-major] Ki-67 Antigen / metabolism. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Diagnosis, Differential. Disease Progression. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Mitotic Index. Neoplasm Staging. Neoplasm, Residual

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 1970 Feb;33(1):80-7 [5418182.001]
  • [Cites] J Neurosurg. 1994 Nov;81(5):666-75 [7931612.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):207-13 [11263500.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4443-51 [14555517.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] Histopathology. 1998 Jul;33(1):64-70 [9726051.001]
  • [Cites] J Neurooncol. 1997 Sep;34(3):241-6 [9258816.001]
  • [Cites] J Neurooncol. 2001 Oct;55(1):1-9 [11804277.001]
  • [Cites] J Neurosurg Sci. 2003 Jun;47(2):65-8 [14618133.001]
  • [Cites] Neuropathol Appl Neurobiol. 1997 Dec;23(6):496-506 [9460716.001]
  • [Cites] Cancer. 1999 May 15;85(10):2249-54 [10326705.001]
  • [Cites] Surg Neurol. 1994 Apr;41(4):299-305 [8165499.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Neurosurgery. 1999 Aug;45(2):409-16 [10449091.001]
  • [Cites] Surg Neurol. 2001 Oct;56(4):228-35 [11738666.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):827-32 [7717450.001]
  • [Cites] Cancer. 1994 Dec 15;74(12):3176-89 [7982181.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] J Neurosurg. 1986 Jan;64(1):58-63 [3941351.001]
  • [Cites] Clin Neuropathol. 1997 May-Jun;16(3):137-42 [9197938.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):9-13 [11763427.001]
  • [Cites] Am J Surg Pathol. 2001 Apr;25(4):472-8 [11257621.001]
  • [Cites] J Neurosurg. 1999 Mar;90(3):455-62 [10067913.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Acta Neuropathol. 1983;61(2):130-4 [6637397.001]
  • [Cites] Acta Neuropathol. 1996;91(5):504-10 [8740231.001]
  • [Cites] Brain Pathol. 1999 Oct;9(4):645-50 [10517503.001]
  • [Cites] Am J Clin Pathol. 2000 Jul;114(1):84-92 [10884803.001]
  • (PMID = 15981101.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen
  •  go-up   go-down


26. Guzman G, Oh S, Shukla D, Engelhard HH, Valyi-Nagy T: Expression of entry receptor nectin-1 of herpes simplex virus 1 and/or herpes simplex virus 2 in normal and neoplastic human nervous system tissues. Acta Virol; 2006;50(1):59-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among tumors, schwannoma, fibrous meningioma, and medulloblastoma were nectin-1 negative.
  • Oligodendroglioma, ependymoma, pilocytic astrocytoma, pleomorphic xanthoastrocytoma, diffuse astrocytoma, anaplastic astrocytoma, glioblastoma multiforme and meningothelial meningioma showed weak focal nectin-1-positivity.


27. Mittal A, Layton KF, Finn SS, Snipes GJ, Opatowsky MJ: Cystic meningioma: unusual imaging appearance of a common intracranial tumor. Proc (Bayl Univ Med Cent); 2010 Oct;23(4):429-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic meningioma: unusual imaging appearance of a common intracranial tumor.
  • Meningiomas are common tumors of the central nervous system that account for approximately 15% of all intracranial tumors and are the most common extra-axial neoplasm.
  • Most meningiomas are benign, although atypical and malignant meningiomas also exist.
  • We present a case of a woman who presented with a history of multiple recent falls, decreased energy, and increased somnolence and was found to have a "cystic meningioma."

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurol India. 2000 Dec;48(4):338-42 [11146597.001]
  • [Cites] Arq Neuropsiquiatr. 2001 Dec;59(4):939-43 [11733842.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1985 Jul;48(7):716-8 [4031920.001]
  • [Cites] Radiographics. 1991 Nov;11(6):1087-106 [1749851.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 Jan-Feb;8(1):127-30 [3101455.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 21240328.001).
  • [ISSN] 1525-3252
  • [Journal-full-title] Proceedings (Baylor University. Medical Center)
  • [ISO-abbreviation] Proc (Bayl Univ Med Cent)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2943459
  •  go-up   go-down


28. Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ, Black PM, Giovannini M, Carroll RS, Kalamarides M: Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res; 2010 Aug 15;16(16):4155-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status.
  • PURPOSE: Meningiomas are the most common central nervous system tumors in the population of age 35 and older.
  • Clinical data supporting histologic malignant progression of meningiomas are sparse and underlying molecular mechanisms are not clearly depicted.
  • EXPERIMENTAL DESIGN: We identified genetic alterations associated with histologic progression of 36 paired meningioma samples in 18 patients using 500K SNP genotyping arrays and NF2 gene sequencing.
  • RESULTS: The most frequent chromosome alterations observed in progressing meningioma samples are early alterations (i.e., present both in lower- and higher-grade samples of a single patient).
  • In our series, NF2 gene inactivation was an early and frequent event in progressing meningioma samples (73%).
  • Chromosome alterations acquired during progression from grade I to grade II meningioma were not recurrent.
  • CONCLUSION: Meningiomas displayed different patterns of genetic alterations during progression according to their NF2 status: NF2-mutated meningiomas showed higher chromosome instability during progression than NF2-nonmutated meningiomas, which had very few imbalanced chromosome segments.
  • This pattern of alterations could thus be used as markers in clinical practice to identify tumors prone to progress among grade I meningiomas.
  • [MeSH-major] Genes, Neurofibromatosis 2. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20682713.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Engenhart-Cabillic R, Farhoud A, Sure U, Heinze S, Henzel M, Mennel HD, Bertalanffy H: Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment. Strahlenther Onkol; 2006 Nov;182(11):641-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
  • BACKGROUND AND PURPOSE: Although meningiomas are typically benign, they occasionally behave in an aggressive fashion and carry a less favorable prognosis.
  • PATIENTS AND METHODS: 16 patients with atypical meningiomas (n = 11) and anaplastic meningiomas (n = 5) were treated in the Departments of Neurosurgery and Radiation Oncology at the University Hospital of Philipps University Marburg, Germany, between 1997 and 2003.
  • Patients with atypical meningioma received radiotherapy only for the recurrent disease.
  • Radiographic findings suggestive of aggressiveness were observed mostly with WHO grade III meningiomas.
  • By comparing the proliferation rate in four cases with atypical meningioma operated twice, the recurrent tumor had a higher proliferation rate than the first tumor in three cases.
  • A special proliferation pattern was noticed in MIB-1 with anaplastic meningiomas.
  • There was no mortality among patients with atypical meningioma, while four out of five patients with anaplastic meningioma died during follow-up.
  • CONCLUSION: Considering the higher rate of recurrence in aggressive meningiomas even after radical surgical excision and the possibility that the recurrent tumor is more aggressive than the original one, surgery should be combined with postoperative fractionated radiotherapy to improve local tumor control.
  • The peculiar focal expression patterns of anaplastic meningioma in MIB-1 might be a marker of such malignant development.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Meningioma / radiotherapy. Meningioma / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17072521.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen
  •  go-up   go-down


30. Miettinen M: From morphological to molecular diagnosis of soft tissue tumors. Adv Exp Med Biol; 2006;587:99-113
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From morphological to molecular diagnosis of soft tissue tumors.
  • Many sarcomas are known to have such fusions, and the demonstration of the fusion transcripts in tumor tissue is of great value in specific diagnosis of synovial sarcoma (SYT-SSX), Ewing sarcoma (EWS-Fli1), clear cell sarcoma (EWS-ATF1), myxoid liposarcoma (FUS-CHOP), and other sarcomas.
  • Demonstration of SYT-SSX and EWS-ATF1 fusion assists in the diagnosis of synovial and clear cell sarcomas in unusual locations, such as the gastrointestinal tract, where these tumors occur with low frequency.
  • In two exceptional instances, the same translocation and gene fusion occurs in two unrelated diseases: ETV6-NTRK fusion in infantile fibrosarcoma and secretory carcinoma of the breast, and ALK-TPM3 fusion in inflammatory myofibroblastic tumor and large cell anaplastic lymphoma.
  • Loss of NF2 tumor suppressor gene in a biallelic fashion is believed to be central in the pathogenesis of neurofibromatosis 2 (NF2) associated and sporadic schwannomas and meningiomas.
  • Intraneural and sclerosing perineuriomas display similar NF2 gene alterations as seen in meningioma, indicating a similar pathogenesis and molecular homology.

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163160.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


31. Ghosh S, Duigou GJ: Decreased replication ability of E1-deleted adenoviruses correlates with increased brain tumor malignancy. Cancer Res; 2005 Oct 1;65(19):8936-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address this, freshly cultured cells from normal human brain and common brain tumors (astrocytomas and meningiomas) were infected using wild-type species C adenoviruses and adenoviruses missing E1A (H5dl312) or E1A plus E1B (H5dl434).
  • In comparison, E1-deleted adenovirus DNA replication was delayed and lower in cells derived from normal brain tissues, meningiomas, and low-grade astrocytomas.
  • Compared with a 5-day average for wild-type infections, advanced cytopathology was noted approximately 4 weeks after H5dl312 or H5dl434 infection of meningioma, astrocytoma, and normal brain cells.
  • Cytopathology was not observed after H5dl312 or H5dl434 infection of glioblastoma, anaplastic astrocytoma, and gliosarcoma cells.
  • [MeSH-minor] Astrocytoma / pathology. Astrocytoma / virology. Cell Line, Tumor. Cytopathogenic Effect, Viral. Disease Progression. Glioblastoma / pathology. Glioblastoma / virology. Gliosarcoma / pathology. Gliosarcoma / virology. Humans. Meningioma / pathology. Meningioma / virology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16204066.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenovirus E1 Proteins
  •  go-up   go-down


32. Rogers L, Gilbert M, Vogelbaum MA: Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol; 2010 Sep;99(3):393-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningiomas of atypical (WHO grade II) histology.
  • Atypical (WHO grade II) meningiomas occupy an intermediate risk group between benign (WHO grade I) and anaplastic (WHO grade III) meningiomas.
  • Although grade II meningiomas have traditionally been recognized in only about 5% of cases, after changes in diagnostic criteria with the current 2007 WHO standards, they now comprise approximately 20-35% of all meningiomas.
  • We will discuss the definition, diagnosis, and treatment of patients with atypical meningioma; review the current phase II cooperative trials; and draw attention to some questions timely for pre-clinical and clinical research.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2009 Jan;64(1):56-60; discussion 60 [19145156.001]
  • [Cites] Radiology. 1987 Aug;164(2):521-6 [3496626.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] Clin Nucl Med. 2005 Nov;30(11):717-20 [16237292.001]
  • [Cites] J Neurooncol. 2007 Aug;84(1):41-7 [17361335.001]
  • [Cites] Neurol Res. 1999 Oct;21(7):640-4 [10555183.001]
  • [Cites] Acta Neurochir (Wien). 1995;135(3-4):171-8 [8748810.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):386-408 [12946028.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):728-34 [12640680.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Eur J Radiol. 2006 Oct;60(1):48-55 [16844335.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):384-90 [10470811.001]
  • [Cites] Neurol Res. 2007 Jan;29(1):43-6 [17427274.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Jun;29(6):1147-52 [18356472.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Clin Radiol. 2007 Feb;62(2):109-19 [17207692.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):99-105 [11163502.001]
  • [Cites] Neuroradiology. 1990;32(6):467-73 [2287373.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]
  • [Cites] Neurosurgery. 1993 Sep;33(3):394-9; discussion 399 [8413869.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63 [17379447.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):817-22 [8598358.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17 (2):345-53 [8938309.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Neurosurgery. 2009 Feb;64(2 Suppl):A7-13 [19165077.001]
  • [Cites] Clin Nucl Med. 2009 Jan;34(1):7-10 [19092373.001]
  • [Cites] J Clin Neurosci. 2003 Sep;10(5):589-93 [12948465.001]
  • [Cites] Neuroradiology. 2006 Aug;48(8):513-20 [16786348.001]
  • [Cites] J Neurosurg. 1999 Dec;91(6):928-34 [10584837.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] Osaka City Med J. 1997 Dec;43(2):209-23 [9540343.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Oct;29(9):1630-5 [18583409.001]
  • [Cites] Chin Med J (Engl). 2008 Dec 5;121(23):2415-9 [19102960.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1 [12823874.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:283-6 [15662826.001]
  • [Cites] Clin Imaging. 2008 Jan-Feb;32(1):22-7 [18164390.001]
  • [Cites] Ann N Y Acad Sci. 1982;381:6-16 [6953802.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Oct;36(10 ):1574-82 [19377904.001]
  • [Cites] Strahlenther Onkol. 1998 Dec;174(12):624-8 [9879349.001]
  • [Cites] Surg Neurol. 2004 Feb;61(2):171-3 [14751635.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):293-6; discussion 296-7 [16953450.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):70-4 [15685038.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Neurosurgery. 2010 Apr;66(4):661-8; discussion 668-9 [20305491.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] Neurosurgery. 2008 May;62(5 Suppl):A19-27; discussion A27-8 [18580776.001]
  • [Cites] Eur Radiol. 2003 Mar;13(3):582-91 [12594562.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] J Neurooncol. 1998 Aug;39(1):65-70 [9760071.001]
  • [Cites] Curr Opin Neurol. 2010 Dec;23(6):563-70 [20885321.001]
  • [Cites] Radiologia. 2009 Jul-Aug;51(4):411-9 [19552929.001]
  • [Cites] J Neurosurg. 1996 Jun;84(6):946-50 [8847588.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:108-11 [8738510.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] J Nucl Med. 1997 Jan;38(1):26-30 [8998144.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Jan;22(1):65-72 [11158890.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E3 [18447742.001]
  • [Cites] Radiology. 2005 Jun;235(3):985-91 [15833979.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E4 [17961041.001]
  • [Cites] J Neuroradiol. 1992;19(1):49-62 [1564530.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):399-406 [19203844.001]
  • (PMID = 20740303.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


33. Boskos C, Feuvret L, Noel G, Habrand JL, Pommier P, Alapetite C, Mammar H, Ferrand R, Boisserie G, Mazeron JJ: Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):399-406
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma.
  • PURPOSE: To evaluate retrospectively the efficacy of conformal fractionated radiotherapy combining proton and photon beams after primary surgery for treatment of atypical and malignant meningiomas.
  • PATIENTS AND METHODS: Between September 1999 and October 2006, 24 patients (12 male, 12 female) with histopathologically proven meningioma (atypical 19, malignant 5) received postoperative combined radiotherapy with a 201-MeV proton beam at the Centre Protontherapie d'Orsay and a high-energy photon beam.
  • The overall mean local relapse-free interval was 27.2 (10-50) months, 28.3 (10-50) months for atypical meningioma and 23 (13-33) months for malignant meningioma.
  • CONCLUSIONS: Postoperative combination of conformal radiotherapy with protons and photons for atypical and malignant meningiomas is a well-tolerated treatment producing long-term tumor stabilization.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Photons / therapeutic use. Protons / therapeutic use. Radiotherapy, Conformal / methods

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19203844.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


34. Shintaku M, Hashimoto K, Okamoto S: Intraventricular meningioma with anaplastic transformation and metastasis via the cerebrospinal fluid. Neuropathology; 2007 Oct;27(5):448-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraventricular meningioma with anaplastic transformation and metastasis via the cerebrospinal fluid.
  • We report a surgical case of intraventricular meningioma that arose in the trigone of the right lateral ventricle of a 61-year-old woman.
  • The tumor exhibited a histopathological appearance of transitional meningioma without cellular atypism in the original specimen, but in the metastatic nodules in the fourth ventricle and spinal subarachnoid space the histopathology was that of typical anaplastic meningioma.
  • Only four cases of anaplastic intraventricular meningioma that developed metastasis via the CSF have been reported.
  • This report presents the fifth case, which is also the second case in which progression from ordinary low-grade meningioma to anaplastic meningioma was demonstrated histopathologically.
  • [MeSH-major] Cerebral Ventricles / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018478.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


35. Moradi A, Semnani V, Djam H, Tajodini A, Zali AR, Ghaemi K, Nikzad N, Madani-Civi M: Pathodiagnostic parameters for meningioma grading. J Clin Neurosci; 2008 Dec;15(12):1370-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathodiagnostic parameters for meningioma grading.
  • Meningiomas are usually slow-growing benign tumors, for which complete removal can be difficult and recurrence is an issue.
  • In this study the relationship between pathodiagnostic parameters, histological grade, and MIB-1 monoclonal antibody expression in meningioma diagnosed over 10 years in Shohada Hospital, Tehran, was assessed.
  • Between January 1997 and December 2006, a total of 4885 intracranial tumors were diagnosed at Shohada Hospital, 378 (7.74%) of which were meningiomas.
  • All slides stained with hematoxylin and eosin were reviewed by two independent pathologists and all the diagnoses reconfirmed; histological anaplasia was classified according to the grading of the WHO Working Group 2000 as benign (Grade I), atypical with incipient signs of anaplasia (Grade II), or overtly anaplastic (Grade III).
  • The mean age of patients with meningiomas was 49.11+/-12.99 years (range 6-78 years, median=50); females outnumbered males by a ratio of 1.7 to 1.
  • Convexity meningiomas were most common, followed by meningiomas of the sphenoid ridge and cerebellopontine angle.
  • Histopathological study of completely resected meningiomas showed that loss of architecture, frequent mitotic figures, a high cellularity, increased nucleo-cytoplasmic ratio, a prominent nucleolus, brain invasion, and necrosis were correlated with the grade of the meningiomas.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18819804.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


36. Combs SE, Edler L, Burkholder I, Rieken S, Habermehl D, Jäkel O, Haberer T, Unterberg A, Wick W, Debus J, Haselmann R: Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial. BMC Cancer; 2010 Nov 09;10:615
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial.
  • BACKGROUND: Treatment standard for patients with atypical or anaplastic meningioma is neurosurgical resection.
  • However, meningiomas are known to be radioresistant tumors, and radiation doses of 60 Gy or higher have been shown to be necessary for tumor control.
  • Moreover, in comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be calculated between 2 and 5 depending on the cell line as well as the endpoint analyzed.First data obtained within the Phase I/II trial performed at GSI in Darmstadt on carbon ion radiotherapy for patients with high-risk meningiomas has shown safety, and treatment results are promising.
  • METHODS/DESIGN: The Phase II-MARCIE-Study will evaluate a carbon ion boost applied to the macroscopic tumor in conjunction with photon radiotherapy in patients with atypical meningiomas after incomplete resection or biopsy.Primary endpoint is progression-free survival, secondary endpoints are overall survival, safety and toxicity.
  • DISCUSSION: Based on published data on the treatment of atypical meningiomas with carbon ions at GSI, the present study will evaluate this treatment concept in a larger patient population and will compare outcome to current standard photon treatment.
  • [MeSH-major] Carbon / therapeutic use. Ions / therapeutic use. Meningioma / radiotherapy. Meningioma / surgery

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] Radiother Oncol. 2010 Apr;95(1):54-9 [20189258.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):501-4 [3042721.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):817-22 [8598358.001]
  • [Cites] Acta Neurochir (Wien). 1995;135(3-4):171-8 [8748810.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):809-16 [15708260.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):767-73 [16306156.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):641-6 [17072521.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):171-7 [17056193.001]
  • [Cites] J Clin Oncol. 2007 Mar 10;25(8):953-64 [17350944.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):449-57 [17363188.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Br J Neurosurg. 2007 Dec;21(6):588-92 [18071986.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1388-93 [18294779.001]
  • [Cites] Int J Radiat Biol. 2009 Feb;85(2):126-37 [19280465.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):803-8 [11395250.001]
  • (PMID = 21062428.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT01166321
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ions; 7440-44-0 / Carbon
  • [Other-IDs] NLM/ PMC2996393
  •  go-up   go-down


37. Nakane Y, Natsume A, Wakabayashi T, Oi S, Ito M, Inao S, Saito K, Yoshida J: Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. J Neurosurg; 2007 Aug;107(2):398-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A.
  • OBJECT: Analysis of meningiomas supports the suggestion that loss of heterozygosity (LOH) of chromosome arm 1p plays an important role in malignancy.
  • The aim of this study was to identify genes related to meningioma progression from the benign state to the atypical and anaplastic states by examining 1p LOH and the promoter methylation of RASSF1A and p73.
  • METHODS: The authors studied 40 surgical specimens (22 WHO Grade I, 11 Grade II, and seven Grade III) obtained in 37 patients with meningioma.
  • CONCLUSIONS: Based on the hypothesis that meningiomas cumulatively acquire genetic alterations and thus progress from the benign to the atypical and anaplastic states, genetic alterations in the methylation status of p73 or RASSF1A along with 1p LOH may result in the malignant transformation of a meningioma.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. DNA-Binding Proteins / genetics. Loss of Heterozygosity / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Nuclear Proteins / genetics. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695396.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


38. Shivane AG, Chakrabarty A, Baborie A, Thiryayi W, Donaldson MH, Ross S: A rare case of recurrent secretory meningioma with malignant transformation. Br J Neurosurg; 2006 Aug;20(4):250-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of recurrent secretory meningioma with malignant transformation.
  • A 72-year-old woman previously operated for a sphenoid-ridge meningioma, now presented with double vision.
  • Histology showed a secretory meningioma with an epithelial-appearing, malignant component.
  • Malignant transformation in a secretory meningioma is not known.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasm Recurrence, Local / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954080.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Das A, Tan WL, Smith DR: p53 point mutation is rare in meningiomas from Singaporean patients. Asian J Surg; 2005 Jan;28(1):7-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 point mutation is rare in meningiomas from Singaporean patients.
  • In Asian populations, meningiomas account for up to 35% of all central nervous system tumours, a significantly higher incidence than in Caucasian populations.
  • While several studies have examined p53 both at the level of the gene and the protein in both benign and malignant meningiomas, its role remains controversial, particularly with regard to the discrepancy between p53 over-expression and gene mutation.
  • We examined 19 benign meningiomas, all of which were known to over-express p53, and eight malignant meningiomas, of which three were known to over-express p53, for mutations in the p53 gene using polymerase chain reaction amplification and direct sequencing of exons 4 to 9, inclusive.
  • Only one single mutation was detected in a benign meningioma, confirming that p53 over-expression in meningiomas is commonly found in the absence of gene mutations, and that despite the significantly higher incidence of meningiomas in some Asian populations, this is not associated with a significantly higher rate of p53 mutations.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691789.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


40. Kim EY, Weon YC, Kim ST, Kim HJ, Byun HS, Lee JI, Kim JH: Rhabdoid meningioma: clinical features and MR imaging findings in 15 patients. AJNR Am J Neuroradiol; 2007 Sep;28(8):1462-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdoid meningioma: clinical features and MR imaging findings in 15 patients.
  • BACKGROUND AND PURPOSE: Rhabdoid meningioma (RM) is a recently described variant of malignant meningioma, with radiologic features currently not well characterized in the medical literature.
  • [MeSH-major] Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / physiopathology. Meningioma / diagnosis. Meningioma / physiopathology
  • [MeSH-minor] Adult. Aged. Cysts / diagnosis. Edema / chemically induced. Edema / etiology. Female. Follow-Up Studies. Humans. Hyperostosis / diagnosis. Hyperostosis / etiology. Male. Middle Aged. Neurosurgical Procedures. Radiotherapy, Adjuvant. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846191.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Söling A, Plugge EM, Schmitz M, Weigle B, Jacob R, Illert J, Holzhausen HJ, Rainov NG: Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors. Int J Oncol; 2007 Jan;30(1):123-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Survivin is a member of the inhibitor of apoptosis protein (IAP) family and is frequently expressed in cancers, including meningiomas and gliomas.
  • Using ELISA and immunoblot analysis we asked whether survivin is capable of eliciting a humoral immune response in patients with meningiomas and gliomas.
  • Survivin-specific antibodies were detected in 5 of 42 (11.9%) patients with meningiomas and 3 of 35 (8.6%) patients with malignant gliomas of the WHO grades 3 and 4, but not in healthy controls.
  • We conclude that patients with meningiomas and malignant gliomas can mount a high-titer IgG immune response against the 'universal' tumor-associated antigen survivin.
  • Anti-survivin antibodies may represent attractive tools for diagnosis and follow-up of brain tumors.
  • [MeSH-minor] Adult. Aged. Apoptosis / immunology. Glioma / immunology. Glioma / pathology. Humans. Immunoglobulin G / blood. Inhibitor of Apoptosis Proteins. Meningioma / immunology. Meningioma / pathology. Middle Aged. Neoplasm Staging. Recombinant Proteins / immunology. Reference Values

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143520.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / BIRC5 protein, human; 0 / Immunoglobulin G; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Recombinant Proteins
  •  go-up   go-down


42. Trinkaus M, Vranic A, Dolenc VV, Lah TT: Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas. Int J Biol Markers; 2005 Jan-Mar;20(1):50-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas.
  • Meningiomas are, in general, slowly growing benign tumors attached to the dura mater and composed of neoplastic meningothelial (arachnoidal) cells.
  • They have a wide range of histopathological appearances and are classified, according to the aggressiveness of their growth and the risk of recurrence, as WHO grade I (benign) meningiomas, WHO grade II (atypical) meningiomas and WHO grade III anaplastic (malignant) meningiomas.
  • As invasion of normal tissue may occur in all grades, independent biological markers are needed to identify the more aggressive and recurrent meningiomas.
  • The lysosomal cysteine proteinases, cathepsins B and L, have been associated with tumor invasiveness and the aim of this study was therefore to evaluate them, together with their endogenous inhibitors stefin B and cystatin C, as potential markers for the aggressiveness of meningiomas.
  • The expression of cathepsins B and L and their inhibitors stefin B and cystatin C in 21 benign (grade I) and 9 atypical (grade II) meningiomas has been compared by immunohistochemical staining, QRT-PCR and Northern blot analysis.
  • The protein levels of cathepsins B (p=0.050) and L (p=0.019) were found to be significantly higher in atypical than in benign meningiomas.
  • Protein and mRNA levels of stefin B (p= 0.007), but not cystatin C, were significantly lower in atypical compared with benign meningiomas.
  • The expression of cathepsins and inhibitors was not different between central and peripheral meningioma tissue or between histological subtypes of meningiomas, with the exception of cathepsin L, the level of which was significantly lower in transitional meningiomas.
  • We conclude that higher protein levels of cathepsins B and L and lower mRNA levels of stefin B are potential diagnostic markers for invasive and aggressive behavior of meningiomas.
  • The diagnostic and prognostic value for relapse of meningioma needs to be confirmed in a larger population of patients.
  • [MeSH-major] Cathepsin B / metabolism. Cathepsins / metabolism. Cystatins / genetics. Cysteine Endopeptidases / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832773.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CST3 protein, human; 0 / CSTB protein, human; 0 / Cystatin C; 0 / Cystatins; 0 / RNA, Messenger; 0 / Receptors, Progesterone; 88844-95-5 / Cystatin B; EC 3.4.- / Cathepsins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / CTSL1 protein, human; EC 3.4.22.15 / Cathepsin L
  •  go-up   go-down


43. Utsuki S, Oka H, Sato Y, Kawano N, Tsuchiya B, Kobayashi I, Fujii K: Invasive meningioma is associated with a low expression of E-cadherin and beta-catenin. Clin Neuropathol; 2005 Jan-Feb;24(1):8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive meningioma is associated with a low expression of E-cadherin and beta-catenin.
  • Invasive meningioma shows benign histological features (WHO grade 1) and the brain expansion at the tumor-brain interface, and recurs more frequently than common meningiomas.
  • To determine the mechanism of brain expansion, we studied the relationship between invasive meningioma and cell adhesion molecules.
  • Immunostaining for E-cadherin (E-CH), N-cadherin (N-CH), beta-catenin, and Ki-67 was performed in 103 meningiomas that consisted of 61 meningothelial meningiomas, 25 fibrous meningiomas, 12 invasive meningiomas and 5 anaplastic meningiomas.
  • All the 61 meningothelial meningiomas, 10 of 12 invasive meningiomas, and 3 of 5 anaplastic meningiomas were positive for both E-CH and beta-catenin, while these were both negative in all of the fibrous meningiomas.
  • In invasive meningiomas, the expansive part of the tumor showed a lower rate (4/12 tumors) of E-CH and beta-catenin positivity, while the central part showed a higher rate (10/12 tumors).
  • The Ki-67 labeling index was higher in invasive and anaplastic meningiomas than in meningothelial meningiomas.
  • These results suggest that a reduction in cell adhesion molecules and increased proliferative activity may be related, which may lead to a better understanding of the mechanism of meningioma expansion in the future.
  • [MeSH-major] Cadherins / metabolism. Cytoskeletal Proteins / metabolism. Meningeal Neoplasms / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology. Trans-Activators / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696778.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cadherins; 0 / Cytoskeletal Proteins; 0 / Ki-67 Antigen; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


44. Balme E, Roth DR, Perentes E: Malignant spinal meningioma in a CD-1 mouse. Exp Toxicol Pathol; 2008 Aug;60(4-5):263-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant spinal meningioma in a CD-1 mouse.
  • Spontaneous meningiomas are extremely rare tumors in small laboratory animals, except in some strains of rats and in the B6C3F1 mouse.
  • Microscopic examination revealed the presence of a malignant meningioma (approximately 3mm in diameter) at the distal lumbar level of the spinal cord, invading the vertebral canal, and bilaterally the ventral and dorsal nerve roots and the dorsal root ganglia.
  • The diagnosis of malignant spinal meningioma was based on the morphologic features of the neoplasm, the evidence of local invasion and the immunohistochemical results.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / veterinary. Meningioma / pathology. Meningioma / veterinary. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / veterinary

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18485685.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Vimentin
  •  go-up   go-down


45. Pelz AF, Klawunde P, Skalej M, Wieacker P, Kirches E, Schneider T, Mawrin C: Novel chromosomal aberrations in a recurrent malignant meningioma. Cancer Genet Cytogenet; 2007 Apr 1;174(1):48-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel chromosomal aberrations in a recurrent malignant meningioma.
  • The molecular basis of tumorigenesis and tumor progression in meningiomas is not fully understood.
  • Here we present results of conventional cytogenetic, fluorescence in situ hybridization (FISH), and comparative genetic hybridization (CGH) analyses in a patient with recurrent anaplastic meningioma.
  • We found complex aberrant karyotype alterations previously described in anaplastic meningiomas, such as 1p, 14q aberration, and a possibly tetraploid karyotype.
  • Our findings of several previously unreported cytogenetic alterations suggest that complex karyotype alterations are a characteristic feature in anaplastic meningiomas.
  • High chromosomal complexity might be associated with a highly aggressive meningioma phenotype.

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17350466.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Cauley K, Jagjivan B, Khan A: Malignant meningioma: computed tomography and magnetic resonance imaging characteristics. Conn Med; 2005 Nov-Dec;69(10):629-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant meningioma: computed tomography and magnetic resonance imaging characteristics.
  • Malignant meningioma is a relatively rare subtype of meningioma demonstrating an aggressive growth pattern, distinct histologic features, and a propensity for recurrence following surgical resection.
  • There has been little consensus regarding imaging features of malignant meningioma, and typically the degree of tumor aggressiveness is determined by pathology.
  • Here we describe a case of malignant meningioma determined to be benign at initial biopsy.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381110.001).
  • [ISSN] 0010-6178
  • [Journal-full-title] Connecticut medicine
  • [ISO-abbreviation] Conn Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


47. Rushing EJ, Bouffard JP, McCall S, Olsen C, Mena H, Sandberg GD, Thompson LD: Primary extracranial meningiomas: an analysis of 146 cases. Head Neck Pathol; 2009 Jun;3(2):116-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extracranial meningiomas: an analysis of 146 cases.
  • Primary extracranial meningiomas are rare neoplasms, frequently misdiagnosed, resulting in inappropriate clinical management.
  • Histologically, the majority of tumors were meningothelial (77.4%), followed by atypical (7.5%), psammomatous (4.1%) and anaplastic (2.7%).
  • The differential diagnosis included a number of mesenchymal and epithelial tumors (paraganglioma, schwannoma, carcinoma, melanoma, neuroendocrine adenoma of the middle ear), depending on the anatomic site of involvement.
  • Meningiomas can present in a wide variety of sites, especially within the head and neck region.
  • Awareness of this diagnosis in an unexpected location will help to avoid potential difficulties associated with the diagnosis and management of these tumors.
  • [MeSH-major] Meningioma / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1995 Oct 1;76(7):1155-65 [8630892.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1984 May-Jun;93(3 Pt 1):282-3 [6732115.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] J Neurosurg Sci. 1997 Sep;41(3):283-92 [9444582.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 Dec;119(6):658-64 [9852544.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] AMA Arch Derm. 1956 Dec;74(6):590-4 [13371911.001]
  • [Cites] Am J Surg. 1960 Sep;100:486-9 [13716296.001]
  • [Cites] Acta Radiol. 2005 Jul;46(4):415-8 [16134320.001]
  • [Cites] Neurosurg Rev. 2006 Jan;29(1):36-40 [16220350.001]
  • [Cites] J Rheumatol. 2006 Sep;33(9):1883-5 [16960947.001]
  • [Cites] Am J Otolaryngol. 1983 Sep-Oct;4(5):297-324 [6416092.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1860-9 [6478422.001]
  • [Cites] AJNR Am J Neuroradiol. 1984 Sep-Oct;5(5):599-604 [6435426.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Am J Surg Pathol. 1986 Dec;10(12):836-43 [3789250.001]
  • [Cites] J Otolaryngol. 1986 Dec;15(6):380-4 [3806773.001]
  • [Cites] Laryngoscope. 1987 Jun;97(6):693-6 [3586809.001]
  • [Cites] Br J Oral Maxillofac Surg. 1987 Dec;25(6):520-5 [3480004.001]
  • [Cites] Laryngoscope. 1990 Jan;100(1):41-8 [2104554.001]
  • [Cites] Am J Otol. 1990 May;11(3):201-4 [2343905.001]
  • [Cites] Aust N Z J Surg. 1990 Oct;60(10):779-86 [2403325.001]
  • [Cites] Neurosurgery. 1991 May;28(5):714-9; discussion 719-20 [1876250.001]
  • [Cites] Acta Neurochir (Wien). 1991;110(1-2):33-7 [1882716.001]
  • [Cites] Laryngoscope. 1992 Dec;102(12 Pt 1):1357-62 [1453842.001]
  • [Cites] Acta Otolaryngol Suppl. 1991;488:1-40 [1843064.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 Jul;33(7):458-62 [7692324.001]
  • [Cites] Am J Otol. 1993 Jul;14(4):403-6 [8238280.001]
  • [Cites] Laryngoscope. 1994 Jul;104(7):814-20 [8022242.001]
  • [Cites] J Dermatol. 1995 Aug;22(8):611-9 [7560462.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):745-8 [16904168.001]
  • [Cites] Surg Neurol. 2007 Jan;67(1):102-5 [17210319.001]
  • [Cites] Adv Clin Path. 1999 Jul;3(3):47-53 [10655573.001]
  • [Cites] J Laryngol Otol. 1999 Dec;113(12):1101-3 [10767926.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):640-50 [10800982.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):898-901 [10835531.001]
  • [Cites] Am J Rhinol. 2001 Jan-Feb;15(1):27-30 [11258651.001]
  • [Cites] Mod Pathol. 2002 May;15(5):543-55 [12011260.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):236-45 [12640104.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):594-611 [12717245.001]
  • [Cites] Acta Otolaryngol. 2004 Jan;124(1):5-7 [14977069.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1129-33 [15133478.001]
  • [Cites] J Neurosurg. 1966 Jul;25(1):83-6 [5947052.001]
  • [Cites] Neurology. 1970 Apr;20(4):368-72 [5534971.001]
  • [Cites] Hum Pathol. 1971 Sep;2(3):453-9 [4330219.001]
  • [Cites] Acta Radiol Diagn (Stockh). 1972 Jul;12(4):419-27 [5055587.001]
  • [Cites] Arch Otolaryngol. 1973 Aug;98(2):102-5 [4723760.001]
  • [Cites] Am J Surg. 1973 Oct;126(4):452-7 [4743832.001]
  • [Cites] J Surg Oncol. 1973 May;5(5):411-20 [4752462.001]
  • [Cites] Cancer. 1974 Sep;34(3):728-44 [4851231.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1976 Jun;41(6):771-6 [1063981.001]
  • [Cites] Laryngoscope. 1976 Aug;86(8):1141-6 [950856.001]
  • [Cites] Laryngoscope. 1978 Sep;88(9 Pt 2 Suppl 12):1-58 [355750.001]
  • [Cites] Am J Otol. 1980 Jan;1(3):171-3 [6969989.001]
  • [Cites] Head Neck Surg. 1983 Mar-Apr;5(4):319-28 [6862940.001]
  • [Cites] Laryngoscope. 1983 Nov;93(11 Pt 1):1397-404 [6633109.001]
  • [Cites] Neurol Med Chir (Tokyo). 1997 Jun;37(6):472-4 [9232100.001]
  • (PMID = 19644540.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Keywords] NOTNLM ; Extracranial / Immunohistochemistry / Meningioma / Prognosis / Radiation / WHO classification
  •  go-up   go-down


48. Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, Lichter P: Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer; 2005 Mar 20;114(2):249-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression.
  • To identify gene expression profiles associated with human meningiomas of different World Health Organization (WHO) malignancy grades, we analyzed 30 tumors (13 benign meningiomas, WHO grade I; 12 atypical meningiomas, WHO grade II; 5 anaplastic meningiomas, WHO grade III) for the expression of 2,600 genes using cDNA-microarray technology.
  • Receiver operator curve (ROC) analysis with a cutoff value of 45% selection probability identified 37 genes with decreased and 27 genes with increased expression in atypical and anaplastic meningiomas, compared to benign meningiomas.
  • However, anaplastic meningiomas could be distinguished from benign meningiomas by differential expression of a distinct set of genes, including several ones associated with cell cycle regulation and proliferation.
  • Taken together, our microarray-based expression profiling revealed interesting novel candidate genes and pathways that may contribute to meningioma progression.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Meningeal Neoplasms / genetics. Meningioma / genetics. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15540215.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Sanz Esponera J: [Meningiomas: new prognostic factors]. An R Acad Nac Med (Madr); 2007;124(2):319-32; discussion 330-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Meningiomas: new prognostic factors].
  • [Transliterated title] Meningiomas. nuevos factores pronósticos.
  • Meningiomas are still defined as benignant tumours although 25% of those tumours will have local recurrance in the follow-up period.
  • The WHO (2000) classification divides meningiomas in three goups: Grade 1 for conventional meningioma.
  • Grade 2 for atypical meningioma and Grade 3 for Anaplastic meningioma.
  • Specific histological variants of meningiomas have been included in grade 2 tumours.
  • Clear cell, rabdoid and papillary meningiomas.
  • We obtained 250 meningiomas from our files and we analyzed 30 inmunohistochemical markers.
  • Several markers can be actually used as prognostic indicators in meningiomas and may allow a more individualized management of patients.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069599.001).
  • [ISSN] 0034-0634
  • [Journal-full-title] Anales de la Real Academia Nacional de Medicina
  • [ISO-abbreviation] An R Acad Nac Med (Madr)
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


50. Ceylan S, Koc K, Anik I: Extended endoscopic approaches for midline skull-base lesions. Neurosurg Rev; 2009 Jul;32(3):309-19; discussion 318-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extended endoscopic transsphenoidal approach was performed for three patients with pituitary adenoma, two patients with craniopharyngioma, one patient with metastatic lesion, one patient with anaplastic germinoma, two patients with chordoma, one patient with chondrosarcoma, one plasmocytoma, and two patients with tuberculum sella meningioma.
  • [MeSH-minor] Adolescent. Adult. Aged. Chondrosarcoma / pathology. Chondrosarcoma / surgery. Chordoma / pathology. Chordoma / surgery. Female. Germinoma / pathology. Germinoma / surgery. Humans. Magnetic Resonance Imaging. Male. Meningioma / pathology. Meningioma / surgery. Middle Aged. Pituitary Neoplasms / surgery. Plasmacytoma / pathology. Plasmacytoma / surgery. Postoperative Complications / epidemiology. Retrospective Studies. Sella Turcica / pathology. Sella Turcica / surgery. Sphenoid Bone / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2001 Jun;94(6):999-1004 [11409533.001]
  • [Cites] Neurosurgery. 2002 Dec;51(6):1358-63; discussion 1363-4 [12445340.001]
  • [Cites] J Neurosurg. 2007 Feb;106(2 Suppl):75-86 [17330530.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(7):715-8; discussion 719 [9781286.001]
  • [Cites] Laryngoscope. 2006 Oct;116(10):1882-6 [17003708.001]
  • [Cites] Neurosurg Focus. 2005 Jul 15;19(1):E6 [16078820.001]
  • [Cites] Minim Invasive Neurosurg. 2008 Apr;51(2):72-5 [18401817.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):298-305; discussion 305 [16937143.001]
  • [Cites] Neurosurg Focus. 2005 Jul 15;19(1):E2 [16078816.001]
  • [Cites] Neurosurg Focus. 2005 Jul 15;19(1):E3 [16078817.001]
  • [Cites] Skull Base. 2007 Feb;17(1):73-8 [17603646.001]
  • [Cites] Neurosurgery. 2004 Oct;55(4):933-40; discussion 940-1 [15458602.001]
  • [Cites] Neurosurgery. 2006 Jul;59(1 Suppl 1):ONS75-83; discussion ONS75-83 [16888556.001]
  • [Cites] Neurosurg Focus. 2005 Jul 15;19(1):E8 [16078822.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):240-8 [17047389.001]
  • [Cites] Neurosurgery. 2007 Sep;61(3 Suppl):24-33; discussion 33-4 [17876230.001]
  • [Cites] Neurosurg Focus. 2007;23(3):E9 [17961027.001]
  • [Cites] Surg Neurol. 2006 Apr;65(4):332-41, discussion 341-2 [16531188.001]
  • [Cites] Neurosurgery. 2006 Jul;59(1 Suppl 1):ONS35-40; discussion ONS35-40 [16888549.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(7):751-6; discussion 756-7 [10955669.001]
  • [Cites] Minim Invasive Neurosurg. 2000 Mar;43(1):33-7 [10794564.001]
  • [Cites] Neurosurgery. 2004 Sep;55(3):539-47; discussion 547-50 [15335421.001]
  • [Cites] Neurosurg Focus. 2005 Jul 15;19(1):E4 [16078818.001]
  • [Cites] Neurosurg Focus. 2005 Jul 15;19(1):E5 [16078819.001]
  • [Cites] J Neurosurg. 2000 Jun;92(6):1028-35 [10839266.001]
  • [Cites] Acta Neurochir (Wien). 1997;139(4):343-7; discussion 347-8 [9202775.001]
  • [Cites] Neurosurgery. 2004 Jul;55(1):239-44; discussion 244-6 [15214996.001]
  • [Cites] J Neurooncol. 2001 Sep;54(2):187-95 [11761435.001]
  • [Cites] J Neurosurg. 2007 Oct;107(4):713-20 [17937213.001]
  • [Cites] Neurosurgery. 2007 Nov;61(5 Suppl 2):229-37; discussion 237-8 [18091237.001]
  • [Cites] J Neurosurg. 2005 May;102(5):832-41 [15926706.001]
  • [Cites] Neurosurgery. 2008 Mar;62(3):556-63; discussion 556-63 [18425005.001]
  • [Cites] Neurosurgery. 2007 Jan;60(1):46-58; discussion 58-9 [17228252.001]
  • [Cites] J Neurosurg. 2007 Mar;106(3):400-6 [17367062.001]
  • [Cites] Neurosurgery. 2001 Jul;49(1):94-100; discussion 100-1 [11440465.001]
  • [Cites] Neurosurgery. 2006 Jul;59(1 Suppl 1):ONS50-7; discussion ONS50-7 [16888551.001]
  • [Cites] Front Horm Res. 2006;34:64-82 [16474216.001]
  • [Cites] Neurosurgery. 2005 Apr;56(2 Suppl):379-89; discussion 379-89 [15794834.001]
  • [Cites] Neurosurgery. 2007 Nov;61(5 Suppl 2):219-27; discussion 228 [18091236.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Feb;47(1):1-8 [15100925.001]
  • (PMID = 19408020.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Puchner MJ, Hans VH, Harati A, Lohmann F, Glas M, Herrlinger U: Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol; 2010 Dec;21(12):2445-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab-induced regression of anaplastic meningioma.

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21041375.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


52. Etienne-Mastroianni B, Girard N, Ginguene C, Tronc F, Vasiljevic A, Vallee B, Cordier JF: [Pulmonary metastases from malignant meningioma]. Rev Mal Respir; 2010 Sep;27(7):764-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary metastases from malignant meningioma].
  • [Transliterated title] Métastases pulmonaires de méningiome malin.
  • INTRODUCTION: Pulmonary metastases from meningioma are rare and present with specific clinical and radiological features.
  • The diagnostic and therapeutic management of metastatic meningioma illustrate the concept of orphan thoracic oncology.
  • CASE REPORT: We report the case of a 58-year-old male, former smoker, with a previous history of atypical meningioma and resected lung adenocarcinoma.
  • Pathological examination of metastasectomy specimens revealed metastatic malignant meningioma.
  • CONCLUSIONS: Pulmonary metastases may occur in malignant meningioma.
  • [MeSH-major] Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 SPLF. Published by Elsevier Masson SAS. All rights reserved.
  • (PMID = 20863979.001).
  • [ISSN] 1776-2588
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


53. Petridis AK, Doukas A, Mahvash M, Dörner L, Hugo HH, Mehdorn HM: A case of rapid-growing anaplastic meningiomas. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of rapid-growing anaplastic meningiomas.
  • Meningiomas are tumours originating from the leptomeningeal covering of the brain and spinal cord and are generally benign and slow growing.
  • Rarely, they show malignant anaplastic characteristics with a high recurrence rate.
  • The present case reports a patient with a giant meningioma over the right frontal lobe who had almost all possible negative prognostic parameters and showed an explosive multifocal recurrence in a timespan of about 5 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Neurochirurgie. 1986;32(2):135-9 [3724943.001]
  • [Cites] Pediatr Neurosurg. 2008;44(2):153-8 [18230932.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):529-38 [17016718.001]
  • [Cites] Br J Neurosurg. 2004 Dec;18(6):617-21 [15799195.001]
  • [Cites] Orbit. 2008;27(4):321-3 [18716974.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E7 [18447746.001]
  • (PMID = 21852998.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3030266
  •  go-up   go-down


54. Estanislau ES, Carvalho GT, Reis BL, de Freitas Barbosa W, Brandão RA, Sousa AA, Oliveira JB: Malignant meningioma with extracranial metastases. Arq Neuropsiquiatr; 2009 Sep;67(3A):730-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant meningioma with extracranial metastases.
  • [MeSH-major] Brain Neoplasms / secondary. Head and Neck Neoplasms / secondary. Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary


55. Fotopoulos AD, Alexiou GA, Goussia A, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Voulgaris S, Tsiouris S: (99m)Tc-Tetrofosmin brain SPECT in the assessment of meningiomas-correlation with histological grade and proliferation index. J Neurooncol; 2008 Sep;89(2):225-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (99m)Tc-Tetrofosmin brain SPECT in the assessment of meningiomas-correlation with histological grade and proliferation index.
  • Meningiomas account for about 30% of all intracranial tumors.
  • We evaluated prospectively whether (99m)Tc-Tetrofosmin ((99m)Tc-TF) uptake in meningiomas correlates with cellular proliferative activity and with tumor grade.
  • We prospectively studied 18 meningioma cases.
  • 14 of 18 patients had benign meningiomas, while the remaining four had anaplastic meningiomas.
  • This pilot study implies that (99m)Tc-TF brain SPECT could prove useful in differentiating benign from anaplastic meningiomas and is a potential indicator of their proliferative activity.
  • [MeSH-major] Brain / diagnostic imaging. Meningeal Neoplasms / diagnostic imaging. Meningioma / diagnostic imaging. Technetium Tc 99m Sestamibi. Tomography, Emission-Computed, Single-Photon

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1987 Apr;27(4):319-22 [3824137.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):209-14 [15072469.001]
  • [Cites] Adv Anat Pathol. 2005 May;12(3):144-8 [15900115.001]
  • [Cites] J Neuropathol Exp Neurol. 1993 Nov;52(6):609-18 [8229080.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Eur J Nucl Med. 1996 Nov;23 (11):1478-84 [8854846.001]
  • [Cites] Neurosurgery. 1992 Apr;30(4):494-7; discussion 497-8 [1584346.001]
  • [Cites] Cancer. 1994 Oct 1;74(7):1921-6 [7521787.001]
  • [Cites] Nucl Med Biol. 2000 Apr;27(3):299-307 [10832087.001]
  • [Cites] Neurol Res. 1999 Oct;21(7):640-4 [10555183.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):970-5 [11567227.001]
  • [Cites] Nucl Med Commun. 2000 Sep;21(9):803-10 [11065152.001]
  • [Cites] J Nucl Med. 1993 Dec;34(12 ):2091-4 [8254393.001]
  • [Cites] J Neurooncol. 2000;46(1):63-70 [10896206.001]
  • [Cites] Curr Opin Oncol. 1997 May;9(3):230-4 [9229144.001]
  • [Cites] Cancer. 1999 May 15;85(10):2249-54 [10326705.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Aug;19(4):411-21 [15453956.001]
  • [Cites] Ann Nucl Med. 1997 Nov;11(4):285-90 [9460519.001]
  • [Cites] Nucl Med Commun. 1998 Feb;19(2):97-105 [9548192.001]
  • [Cites] J Nucl Cardiol. 1995 Jul-Aug;2(4):317-26 [9420806.001]
  • [Cites] Cancer. 1988 Sep 1;62(5):989-93 [3409179.001]
  • [Cites] Neurosurgery. 1995 Sep;37(3):478-82; discussion 483 [7501113.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):820-7 [15785954.001]
  • [Cites] Int J Oncol. 2003 Mar;22(3):639-49 [12579319.001]
  • [Cites] Cancer. 1994 Dec 15;74(12):3176-89 [7982181.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Nucl Med. 1993 Dec;34(12 ):2085-9 [8254391.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1036-44; discussion 1044-5 [7885547.001]
  • [Cites] Br J Cancer. 1992 Aug;66(2):373-85 [1503912.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):293-6; discussion 296-7 [16953450.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):945-52 [15937304.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):19-30 [16078103.001]
  • [Cites] J Neurooncol. 2008 Feb;86(3):359-60 [17634740.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:108-11 [8738510.001]
  • [Cites] Acta Neuropathol. 1996;91(5):504-10 [8740231.001]
  • [Cites] Br J Neurosurg. 2004 Aug;18(4):357-61 [15702834.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Jun;16(2):153-7 [9261740.001]
  • [Cites] Breast Cancer Res. 2004;6(2):R56-62 [14979918.001]
  • [Cites] Cancer Biother Radiopharm. 2005 Jun;20(3):249-59 [15989470.001]
  • [Cites] Ann Nucl Med. 2007 Jul;21(5):293-8 [17634847.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(1):26-31; discussion 31-2 [9522904.001]
  • [Cites] Expert Rev Med Devices. 2005 Mar;2(2):191-6 [16293055.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):373-80 [8625247.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):207-8 [16575536.001]
  • [Cites] Neuro Oncol. 2008 Feb;10 (1):104-5 [18055861.001]
  • [Cites] J Nucl Med. 1998 May;39(5):802-6 [9591579.001]
  • (PMID = 18458817.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


56. Maes L, Van Neste L, Van Damme K, Kalala JP, De Ridder L, Bekaert S, Cornelissen M: Relation between telomerase activity, hTERT and telomere length for intracranial tumours. Oncol Rep; 2007 Dec;18(6):1571-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study analysed the telomerase activity, hTERT protein and telomere length in meningiomas and gliomas in relation to their WHO grading.
  • Telomerase activity was detected in 3 of 35 (8.6%) screened meningiomas (1 benign, 1 atypical and 1 malignant meningioma).
  • For hTERT expression, 56.4% of meningiomas were positive with a mean labelling index (hTERT LI) of 31.3% (SD=26.5) for the hTERT positive meningiomas.
  • The mean telomere length for meningiomas was 6.983 kb (SD=1.969).
  • The anaplastic astrocytoma had a telomere length of 4.903 kb and the glioblastomas 5.767 kb (SD=2.042).
  • These results indicate that telomere shortening may be a critical step in pathogenesis of atypical and malignant meningiomas and gliomas.
  • [MeSH-major] Brain Neoplasms / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology. Telomerase / metabolism. Telomere / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17982646.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


57. Petrovic NS, Grujicic D, Artiko VM, Sobic-Saranovic DP, Gajic MM, Jaksic E, Grajic MM, Antonovic OJ, Petrovic MN, Obradovic VB: Investigation of blood perfusion and metabolic activity of brain tumours in adults by using 99mTc-methoxyisobutylisonitrile. Nucl Med Commun; 2010 Nov;31(11):962-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Mean P of various brain tumours (low-grade gliomas 0.98, anaplastic gliomas 1.14, glioblastoma multiforme 1.20, metastases 1.09, lymphomas 1.08) differ little from each other and do not exceed maximal physiologic regional variations of cerebral perfusion (1.33), with the exception of meningioma (1.87, F=2.83, P=0.015).
  • The receiver operating characteristics curve analysis of P showed that for the cut-off value of 1.45 the sensitivity for distinguishing meningioma from other tumours is 75%, specificity 87%, positive predictive value 33% and negative predictive value 97%.
  • Mean E of malignant brain tumours (8.3, n=31, 23 primary, eight secondary), except anaplastic gliomas (3.5, n=5), differed significantly (P=0.02) from those of benign gliomas (3, n=9) but not from that of meningioma (11.9, n=4).
  • The cut-off value for distinguishing malignant from benign lesions on the basis of E set at 4.8 resulted in sensitivity 67%, specificity 75%, accuracy 70%, positive predictive value 80% and negative predictive value 60%.
  • D and R showed tendency of wash-out of MIBI from meningiomas, but otherwise did not improve the results substantially.
  • If the perfusion index is less than 1.45, then meningioma can be ruled out.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20802363.001).
  • [ISSN] 1473-5628
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


58. Lee GC, Choi SW, Kim SH, Kwon HJ: Multiple extracranial metastases of atypical meningiomas. J Korean Neurosurg Soc; 2009 Feb;45(2):107-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple extracranial metastases of atypical meningiomas.
  • Meningiomas are usually benign neoplasms in which extracranial metastases occur very rarely.
  • We report a case of multiple extracranial metastases of an atypical meningioma following a local recurrence.
  • We performed a total mass removal, and the histopathologic findings were consistent with benign meningioma.
  • Eight months later, the meningioma recurred.
  • The histopathologic findings showed atypical meningioma.
  • The histopathologic findings of the spinal tumors showed atypical meningioma.
  • The results from perirenal biopsies were consistent with metastatic meningioma.
  • In conclusion, extracranial metastasis as well as local recurrence must be considered in atypical or anaplastic meningioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2008;204(5):305-14 [18374497.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Mar 15;25(6):727-31 [10752106.001]
  • [Cites] J Neurosurg. 1964 Dec;21:1098-102 [14281384.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Neuropathol Appl Neurobiol. 1997 Dec;23(6):496-506 [9460716.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(10):1172-7; discussion 1177-8 [8955436.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):478-82 [2915253.001]
  • [Cites] J Neurosurg. 1985 May;62(5):763-6 [3989597.001]
  • [Cites] AJNR Am J Neuroradiol. 1982 May-Jun;3(3):267-76 [6805276.001]
  • [Cites] Br J Cancer. 1978 Apr;37(4):644-7 [646935.001]
  • [Cites] Cancer. 1970 Oct;26(4):832-41 [5528265.001]
  • [Cites] Anticancer Drugs. 2003 Mar;14(3):247-50 [12634620.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] Neurosurg Rev. 2006 Jan;29(1):36-40 [16220350.001]
  • (PMID = 19274122.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2651555
  • [Keywords] NOTNLM ; Anaplastic meningioma / Atypical meningioma / Extracranial metastasis
  •  go-up   go-down


59. Zhang H, Rödiger LA, Shen T, Miao J, Oudkerk M: Perfusion MR imaging for differentiation of benign and malignant meningiomas. Neuroradiology; 2008 Jun;50(6):525-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perfusion MR imaging for differentiation of benign and malignant meningiomas.
  • INTRODUCTION: Our purpose was to determine whether perfusion MR imaging can be used to differentiate benign and malignant meningiomas on the basis of the differences in perfusion of tumor parenchyma and/or peritumoral edema.
  • METHODS: A total of 33 patients with preoperative meningiomas (25 benign and 8 malignant) underwent conventional and dynamic susceptibility contrast perfusion MR imaging.
  • The independent samples t-test was used to determine whether there was a statistically significant difference in the mean rCBV and rMTE ratios between benign and malignant meningiomas.
  • RESULTS: The mean maximal rCBV values of benign and malignant meningiomas were 7.16+/-4.08 (mean+/-SD) and 5.89+/-3.86, respectively, in the parenchyma, and 1.05+/-0.96 and 3.82+/-1.39, respectively, in the peritumoral edema.
  • The differences in rCBV and rMTE values between benign and malignant meningiomas were not statistically significant (P>0.05) in the parenchyma, but both were statistically significant (P<0.05) in the peritumoral edema.
  • CONCLUSION: Perfusion MR imaging can provide useful information on meningioma vascularity which is not available from conventional MRI.
  • Measurement of maximal rCBV and corresponding rMTE values in the peritumoral edema is useful in the preoperative differentiation between benign and malignant meningiomas.
  • [MeSH-major] Magnetic Resonance Angiography. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Clin Imaging. 2002 Jul-Aug;26(4):243-9 [12140153.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Sep;24(8):1554-9 [13679270.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Jan-Feb;13(1):29-37 [1595462.001]
  • [Cites] Radiology. 1994 Apr;191(1):41-51 [8134596.001]
  • [Cites] Arch Pathol Lab Med. 1997 May;121(5):481-4 [9167601.001]
  • [Cites] Neuroradiology. 2006 Dec;48(12):867-74 [17013587.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):936-44 [10091773.001]
  • [Cites] Radiology. 1999 Jun;211(3):791-8 [10352608.001]
  • [Cites] J Clin Neurosci. 2006 Jan;13(1):136-9 [16410217.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Feb;27(2):409-17 [16484420.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Mar;27(3):475-87 [16551981.001]
  • [Cites] Cancer. 1998 May 1;82(9):1749-55 [9576298.001]
  • (PMID = 18379768.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ PMC2440923
  •  go-up   go-down


60. Hsu CC, Pai CY, Kao HW, Hsueh CJ, Hsu WL, Lo CP: Do aggressive imaging features correlate with advanced histopathological grade in meningiomas? J Clin Neurosci; 2010 May;17(5):584-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do aggressive imaging features correlate with advanced histopathological grade in meningiomas?
  • Atypical and malignant meningiomas are more likely to recur than benign meningiomas.
  • We aimed to distinguish atypical and malignant meningiomas from benign meningiomas based on imaging findings.
  • Between 2004 and 2007, a total of 75 patients with resected intracranial meningiomas were retrospectively reviewed.
  • Histopathological grades were assigned as benign and atypical/malignant meningiomas according to the World Health Organization (WHO) classification.
  • There were 59 benign and 16 atypical/malignant meningiomas.
  • Only intratumoral cystic change and extracranial tumor extension through the skull base foramina were more prevalent in atypical/malignant meningiomas (p=0.001).
  • Hence, these two imaging features might be potential markers of atypical/malignant meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / radiography. Meningioma / pathology. Meningioma / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20219376.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


61. Zhao X, Sun JL, Wang ZG, Zhang TG, Wang CW, Ji Y: Clinical analysis for an unusual large cystic meningioma: case report and review of the literature. Clin Neurol Neurosurg; 2008 Jun;110(6):605-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis for an unusual large cystic meningioma: case report and review of the literature.
  • The authors report the case of a 17-year-old boy with an unusual large cystic meningioma (Nauta type II) in the right hemisphere.
  • Histological examination displayed an anaplastic meningioma, of which the cyst wall also consisted of meningioma tissue.
  • To the best of the authors' knowledge, such an unusual case of cystic meningioma has not been reported.
  • The authors review the literature with reference to intratumoral cyst associated with meningiomas, analyze the unusual imaging appearances of this patient, and explore the mechanism of cyst formation.
  • The mechanism of cyst formation associated with meningiomas is not perfectly understood.
  • [MeSH-major] Cysts / pathology. Cysts / surgery. Meningioma / pathology. Meningioma / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384935.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


62. Regel JP, Schoch B, Sandalcioglu IE, Wieland R, Westermeier C, Stolke D, Wiedemayer H: Malignant meningioma as a second malignancy after therapy for acute lymphatic leukemia without cranial radiation. Childs Nerv Syst; 2006 Feb;22(2):172-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant meningioma as a second malignancy after therapy for acute lymphatic leukemia without cranial radiation.
  • RATIONALE: Meningiomas in the pediatric age group are very rare tumors, comprising about 1-4.2% of all primary pediatric intracranial tumors.
  • CASE REPORT: We present a 17-year-old patient who suffered from an intraventricular malignant meningioma.
  • In December 2001, 13 years after diagnosis of cALL, he complained of headache, vomiting, and walking difficulties.
  • Histological diagnosis revealed a malignant papillary meningioma.
  • After removal of a recurrent meningioma 16 months later, he received local radiotherapy.
  • CONCLUSION: Pathogenetic mechanisms, treatment options, and prognosis of meningiomas and secondary malignancies of this age group are discussed.
  • [MeSH-major] Drug-Related Side Effects and Adverse Reactions. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Second Primary / etiology

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Dec 15;95(12):2562-70 [12467071.001]
  • [Cites] Pediatr Neurosurg. 2001 May;34(5):264-7 [11423779.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Neurol Med Chir (Tokyo). 1996 Aug;36(8):598-601 [8831206.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):406-16 [10958549.001]
  • [Cites] Childs Nerv Syst. 2001 Nov;17 (11):656-62 [11734983.001]
  • [Cites] Med Phys. 2001 Nov;28(11):2387-8 [11764047.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4257-64 [12036851.001]
  • [Cites] Prog Exp Tumor Res. 1987;30:247-54 [3628810.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):964-9 [11420471.001]
  • (PMID = 16456690.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Nakamura Y, Kanemura Y, Yamada T, Sugita Y, Higaki K, Yamamoto M, Takahashi M, Yamasaki M: D2-40 antibody immunoreactivity in developing human brain, brain tumors and cultured neural cells. Mod Pathol; 2006 Jul;19(7):974-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some brain tumors such as anaplastic ependymoma, some medulloblastomas, glioblastoma, pineal germinoma, craniopharyngioma, choroid plexus papilloma, choroid plexus carcinoma, and meningioma showed positive immunoreactivity with D2-40.
  • Therefore, D2-40 antibody is considered a useful marker for research on developing brain and diagnosis of brain tumors, differentiation between choroid plexus carcinoma and metastatic carcinoma.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648867.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Neoplasm; 0 / monoclonal antibody D2-40; 0 / oncofetal antigens
  •  go-up   go-down


64. Simon M, Boström J, Koch P, Schramm J: Interinstitutional variance of postoperative radiotherapy and follow up for meningiomas in Germany: impact of changes of the WHO classification. J Neurol Neurosurg Psychiatry; 2006 Jun;77(6):767-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interinstitutional variance of postoperative radiotherapy and follow up for meningiomas in Germany: impact of changes of the WHO classification.
  • OBJECTIVE: To document and critically analyse the impact of the revised WHO 2000 histological classification for meningiomas on postoperative radiotherapy/radiosurgery indications and MRI follow up protocols.
  • METHODS: The current (2000) WHO classification was used to grade 57 meningiomas treated surgically at one institution.
  • All German neurosurgical departments carrying out intracranial microsurgery were asked to detail their guidelines for radiation therapy and follow up for meningiomas of different WHO grades.
  • RESULTS: Use of the current criteria downgraded seven of 15 atypical meningiomas (WHO grade II, MII) to grade I (MI), and four of six anaplastic tumours (WHO grade III, MIII) to grade II.
  • CONCLUSIONS: Correlative studies combining treatment and outcome data with a standardised histopathological analysis are warranted to define properly the indications for radiotherapy/radiosurgery and follow up protocols after surgery for meningiomas of different histological grades.
  • The relatively large number of meningiomas classified as atypical/WHO grade II in current practice would argue against an uncritically aggressive approach to these tumours.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Staging / methods. Practice Patterns, Physicians' / statistics & numerical data

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Jan;68(1):25-8 [10601396.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):315-21 [7673018.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):567-74; discussion 574-5 [10719852.001]
  • [Cites] J Neurosurg. 2000 May;92(5):832-40 [10794298.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3547-53 [11481362.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1 [12823874.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):817-22 [8598358.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):177-88 [9524097.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):446-53; discussion 453-4 [9526976.001]
  • [Cites] J Neurosurg. 1998 May;88(5):831-9 [9576250.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Neurosurg Clin N Am. 1999 Apr;10(2):317-25 [10099096.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] J Neurosurg. 1999 May;90(5):823-7 [10223446.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Surg Neurol. 1985 Aug;24(2):165-72 [4012573.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Am J Clin Oncol. 1986 Aug;9(4):337-40 [3751972.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] J Neurosurg. 1986 Dec;65(6):790-4 [3772477.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):545-7 [2398385.001]
  • [Cites] J Neurosurg. 1992 Oct;77(4):616-23 [1527622.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] J Neuropathol Exp Neurol. 1994 May;53(3):247-55 [7909837.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):222-4 [7616265.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • (PMID = 16306156.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2077452
  •  go-up   go-down


65. Hahn HP, Bundock EA, Hornick JL: Immunohistochemical staining for claudin-1 can help distinguish meningiomas from histologic mimics. Am J Clin Pathol; 2006 Feb;125(2):203-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining for claudin-1 can help distinguish meningiomas from histologic mimics.
  • The histologic distinction between meningiomas and other tumors of the central nervous system occasionally can be difficult.
  • Claudin-1 is a tight junction-associated protein recently shown to be expressed in anaplastic meningiomas.
  • The purpose of this study was to determine whether immunohistochemical staining for claudin-1 could help distinguish meningiomas from histologic mimics, compared with commonly used markers.
  • Tissue sections from 10 meningothelial meningiomas, 20 fibrous meningiomas, 10 atypical meningiomas, 7 solitary fibrous tumors of the meninges, 5 meningeal hemangiopericytomas, and 7 vestibular schwannomas were stained immunohistochemically for claudin-1, epithelial membrane antigen, S-100 protein, CD34, and glial fibrillary acidic protein.
  • In total, 21 (53%) of 40 meningiomas were immunoreactive for claudin-1, whereas none of the other tumors were positive.
  • Claudin-1 seems to be a specific marker for meningiomas in this context.
  • Although its sensitivity is relatively low, claudin-1 may be helpful in a panel of immunostains to distinguish meningiomas from histologic mimics.
  • [MeSH-major] Membrane Proteins / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Antigens, CD34 / analysis. Claudin-1. Diagnosis, Differential. Hemangiopericytoma / chemistry. Hemangiopericytoma / pathology. Humans. Immunohistochemistry. Mucin-1 / analysis. Staining and Labeling

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16393681.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Membrane Proteins; 0 / Mucin-1
  •  go-up   go-down


66. Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S: Genomic landscape of meningiomas. Brain Pathol; 2010 Jul;20(4):751-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic landscape of meningiomas.
  • Meningiomas are one of the most common adult brain tumors.
  • Currently, the molecular determinants predicting recurrence and malignant transformation are lacking.
  • We performed retrospective global genetic and genomic analysis of 85 meningioma samples of various grades.
  • In addition to chromosome 22q loss, which was detected in the majority of clinical samples, chromosome 6q and 14q loss was significantly more common in recurrent tumors and was associated with anaplastic histology.
  • Five "classes" of meningiomas were detected by gene expression analysis that correlated with copy number alterations, recurrent status and malignant histology.
  • These classes more accurately identified recurrent tumors relative to Ki-67 index and extent of surgical resection, and highlight substantial expression heterogeneity between meningiomas.
  • These data offer the most complete description of the genomic landscape of meningiomas, and provide broad genomic information that may be used to further stratify meningioma patients into prognostic risk groups.

  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):249-56 [15540215.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4051-8 [15899794.001]
  • [Cites] World J Gastroenterol. 2005 Aug 28;11(32):5057-60 [16124066.001]
  • [Cites] Am J Hum Genet. 2005 Nov;77(5):709-26 [16252233.001]
  • [Cites] Neurosurg Focus. 2005 Nov;19(5):E9 [16398473.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] DNA Res. 2007 Feb 28;14(1):1-11 [17363414.001]
  • [Cites] J Biol Chem. 2007 Jul 27;282(30):21962-72 [17545167.001]
  • [Cites] Genomics. 1996 Aug 15;36(1):112-7 [8812422.001]
  • [Cites] Mol Cancer. 2007;6:64 [17937814.001]
  • [Cites] Genome Biol. 2007;8(6):R112 [17570842.001]
  • [Cites] Childs Nerv Syst. 2008 Jul;24(7):855-7 [18236049.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):598-603 [9892679.001]
  • [Cites] Hum Mol Genet. 2000 Jun 12;9(10):1495-500 [10888600.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):199-201 [11161377.001]
  • [Cites] Nat Cell Biol. 2002 Apr;4(4):317-22 [11901424.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Oncogene. 2003 Apr 17;22(15):2361-73 [12700671.001]
  • [Cites] Oncogene. 2003 Jul 31;22(31):4918-23 [12894235.001]
  • [Cites] Neurosurgery. 2004 Jan;54(1):55-63; discussion 63-4 [14683541.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):1014-20 [14749765.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12734-43 [14718544.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):221-6 [15072471.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):210-8 [15309910.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1087-92 [15492797.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):499-509 [15509483.001]
  • [Cites] Neurosurgery. 2004 Nov;55(5):1163-73 [15509323.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1521-8 [7731706.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10 [10214357.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):167-74 [10222437.001]
  • [ErratumIn] Brain Pathol. 2011 Jul;21(4):478
  • (PMID = 20015288.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS052108-05; United States / NINDS NIH HHS / NS / U24 NS052108; United States / NINDS NIH HHS / NS / U24 NS052108-05; United States / NINDS NIH HHS / NS / U24NS052108
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS161003; NLM/ PMC3167483
  •  go-up   go-down


67. Pfister C, Ritz R, Pfrommer H, Bornemann A, Tatagiba MS, Roser F: Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas? Neurosurg Focus; 2007;23(4):E8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas?
  • OBJECT: The current treatment for recurrent or malignant meningiomas with adjuvant therapies has not been satisfactory, and there is an intense interest in evaluating new molecular markers to act as therapeutic targets.
  • Enzymes of the arachidonic acid (AA) cascade such as cyclooxygenase (COX)-2 or 5-lipoxygenase (5-LO) are upregulated in a number of epithelial tumors, but to date there are hardly any data about the expression of these markers in meningiomas.
  • To find possible targets for chemotherapeutic intervention, the authors evaluated the expression of AA derivatives at different molecular levels in meningiomas.
  • METHODS: One hundred and twenty-four meningioma surgical specimens and normal human cortical tissue samples were immunohistochemically and cytochemically stained for COX-2, COX-1, 5-LO, and prostaglandin E receptor 4 (PTGER4).
  • RESULTS: Sixty (63%) of 95 benign meningiomas, 21 (88%) of 24 atypical meningiomas, all five malignant meningiomas, and all normal human cortex samples displayed high COX-2 immunoreactivity.
  • The PCR analysis demonstrated no changes in eicosanoid expression among meningiomas of different World Health Organization grades and in normal human cortical and dura mater tissue.
  • CONCLUSIONS: Eicosanoid derivatives COX-1, COX-2, 5-LO, and PTGER4 enzymes show a high universal expression in meningiomas but are not upregulated in normal human cortex and dura tissue.
  • This finding of the ubiquitous presence of these enzymes in meningiomas offers an excellent baseline for testing upcoming chemotherapeutic treatments.
  • [MeSH-major] Eicosanoids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961045.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Eicosanoids; 0 / PTGER4 protein, human; 0 / RNA, Messenger; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP4 Subtype; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


68. Ferchichi L, Bellil S, Ben Hammouda K, Bellil K, Mekni A, Bettaieb I, Haouet S, Khaldi MM, Zitouna K, Kchir N: Anaplastic secretory meningioma: a case report. Pathologica; 2006 Apr;98(2):153-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic secretory meningioma: a case report.
  • Secretory meningiomas are rare histological subtypes of meningiomas with benign biological behaviour.
  • In this study, the authors describe the first case of secretory meningioma with many mitotic figures and brain invasion, and discuss the clinicopathologic features including immunohistochemical staining profile and ultrastructural appearance of this tumour.
  • The histological diagnosis was secretory meningioma with many mitotic figures, a high MIB-1 labeling index and a brain invasion.
  • [MeSH-major] Frontal Lobe / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929789.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


69. Barski D, Wolter M, Reifenberger G, Riemenschneider MJ: Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol; 2010 May;20(3):623-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas.
  • The gene for the tissue inhibitor of metalloproteinase 3 (TIMP3) on 22q12.3 had been reported to be inactivated by promoter methylation in various types of cancers, with controversial findings in meningiomas.
  • We performed direct sodium bisulfite sequencing in a series of 50 meningiomas, including 27 benign meningiomas [World Health Organization (WHO) grade I], 11 atypical meningiomas (WHO grade II) and 12 anaplastic meningiomas (WHO grade III), and found hypermethylation of TIMP3 in 67% of anaplastic meningiomas, but only 22% of atypical and 17% of benign meningiomas.
  • Moreover, TIMP3 methylation scores were significantly inversely correlated with TIMP3 mRNA expression levels (P = 0.0123), and treatment of the meningioma cell line Ben-Men-1 with demethylating agents induced an increased TIMP3 mRNA expression.
  • TIMP3 is located in the chromosomal band 22q12, the allelic loss of which occurs early in meningioma tumorigenesis and preferentially targets the NF2 tumor suppressor gene.
  • In our tumor panel, all meningiomas with TIMP3 hypermethylation--except for a single case--exhibited allelic losses on 22q12.3.
  • Thus, TIMP3 inactivation by methylation seems fairly exclusive to meningiomas with allelic losses on 22q12 but--in contrast to NF2 mutation--appears to be involved in meningioma progression as it is associated with a more aggressive, high-grade meningioma phenotype.
  • [MeSH-major] Chromosomes, Human, Pair 22 / genetics. DNA Methylation / genetics. Loss of Heterozygosity / genetics. Meningeal Neoplasms / genetics. Meningeal Neoplasms / metabolism. Meningioma / genetics. Meningioma / metabolism. RNA Interference / physiology. Tissue Inhibitor of Metalloproteinase-3 / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922547.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / TIMP3 protein, human; 0 / Tissue Inhibitor of Metalloproteinase-3
  •  go-up   go-down


70. Kalamarides M, Stemmer-Rachamimov AO, Takahashi M, Han ZY, Chareyre F, Niwa-Kawakita M, Black PM, Carroll RS, Giovannini M: Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. Brain Pathol; 2008 Jan;18(1):62-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.
  • Meningiomas account for approximately 30% of all primary central nervous system tumors and are found in half of neurofibromatosis type 2 patients often causing significant morbidity.
  • Although most meningiomas are benign, 10% are classified as atypical or anaplastic, displaying aggressive clinical behavior.
  • Biallelic inactivation of the neurofibromatosis 2 (NF2) tumor suppressor is associated with meningioma formation in all NF2 patients and 60% of sporadic meningiomas.
  • Deletion of the p16(INK4a)/p14(ARF) locus is found in both benign and malignant meningiomas, while mutation of the p53 tumor suppressor gene is uncommon.
  • Previously, we inactivated Nf2 in homozygous conditional knockout mice by adenoviral Cre delivery and showed that Nf2 loss in arachnoid cells is rate-limiting for meningioma formation.
  • Here, we report that additional nullizygosity for p16(Ink4a) increases the frequency of meningioma and meningothelial proliferation in these mice without modifying the tumor grade.
  • In addition, by using magnetic resonance imaging (MRI) to screen a large cohort of mutant mice, we were able to detect meningothelial proliferation and meningioma development opening the way to future studies in which therapeutic interventions can be tested as preclinical assessment of their potential clinical application.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / genetics. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology. Neurofibromin 2 / genetics


71. Widdel L, Kleinschmidt-DeMasters BK, Kindt G: Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema. World Neurosurg; 2010 Jul;74(1):165-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema.
  • OBJECTIVE: To report two examples of benign meningiomas in which metastatic tumor deposits from the patient's hematopoietic neoplasm to the meningioma caused significant peritumoral edema, necessitating semiemergent surgical resection.
  • Clinical suspicion in both patients was an atypical or anaplastic meningioma due to the edema.
  • RESULTS: One patient had multiple myeloma associated with extensive necrosis within his otherwise benign convexity meningioma; first diagnosis of his IgG, kappa-restricted plasma cell dyscrasia was made from this tumor-to-tumor meningioma specimen.
  • The second patient carried a diagnosis of marginal zone lymphoma but then presented 5 years later with symptoms referable to a large dural-based mass with significant surrounding edema, prompting surgical removal.
  • Dural marginal zone lymphoma was identified within epidural, intradural, and subdural spaces, in the same location as an underlying benign meningioma.
  • CONCLUSIONS: Although rare, neurosurgeons should be aware of the entity of tumor-to-tumor metastasis as, in large series, meningiomas are the third most frequent recipient tumor type and pituitary adenomas, the fifth most frequent, probably reflecting their rich vascularity.
  • [MeSH-major] Brain Edema / etiology. Image Processing, Computer-Assisted. Lymphoma, B-Cell, Marginal Zone / diagnosis. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Meningioma / diagnosis. Multiple Myeloma / diagnosis. Multiple Myeloma / secondary. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Brain / pathology. Brain / surgery. Diagnosis, Differential. Female. Humans. Male. Meninges / pathology. Meninges / surgery. Middle Aged

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21300009.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Zhou K, Wang G, Wang Y, Jin H, Yang S, Liu C: The potential involvement of E-cadherin and beta-catenins in meningioma. PLoS One; 2010;5(6):e11231
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential involvement of E-cadherin and beta-catenins in meningioma.
  • OBJECTIVE: To investigate the potential involvements of E-cadherin and beta-catenin in meningioma.
  • METHODS: Immunohistochemistry staining was performed on samples from patients with meningioma.
  • The expression of E-cadherin and beta-catenin in meningioma was analyzed by its relationship with WHO2007 grading, invasion, peritumoral edema and postoperative recurrence.
  • RESULTS: The positive rates of E-cadherin in meningioma WHO I, II, III were 92.69%, 33.33% and 0, respectively, (P<0.05); while the positive rates of beta-catenin in meningioma WHO I, II, III were 82.93%, 33.33% and 20.00%, respectively, (P<0.05).
  • The positive rate of E-cadherin in meningioma without invasion (94.12%) was higher than that with invasion (46.67%) (P<0.05).
  • The difference in the positive rate of beta-catenin between meningioma without invasion (88.24%) and meningioma with invasion (33.33%, P<0.05) was also statically significant.
  • The positive rates of E-cadherin in meningioma with peritumoral edema 0, 1, 2, 3 were 93.75%, 85.71%, 60.00% and 0 respectively, (P<0.05); the positive rates of beta-catenin in meningioma with peritumoral edema 0, 1, 2, 3 were 87.50%, 85.71%, 30.00% and 0 respectively, (P<0.01).
  • The positive rates of E- cadherin in meningioma with postoperative recurrence were 33.33%, and the positive rate with postoperative non-recurrence was 90.00% (P<0.01).
  • The positive rates of beta-catenin in meningioma with postoperative recurrence and non-recurrence were 11.11%, 85.00%, respectively (P<0.01).
  • CONCLUSION: The expression levels of E- cadherin and beta-catenin correlated closely to the WHO 2007 grading criteria for meningioma.
  • In atypical or malignant meningioma, the expression levels of E-cadherin and beta-catenin were significantly lower.
  • The expression levels of E- cadherin and beta-catenin were also closely correlated with the invasion status of meningioma, the size of the peritumoral edema and the recurrent probabilities of the meningioma, all in an inverse correlationship.
  • Taken together, the present study provided novel molecular targets in clinical treatments to meningioma.
  • [MeSH-major] Cadherins / metabolism. Meningioma / metabolism. beta Catenin / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):996-1001 [15986431.001]
  • [Cites] Clin Neuropathol. 2005 Jan-Feb;24(1):8-12 [15696778.001]
  • [Cites] Histopathology. 2006 Aug;49(2):178-87 [16879395.001]
  • [Cites] Rev Med Chil. 2006 Aug;134(8):1002-9 [17130988.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5A):3083-9 [17970048.001]
  • [Cites] Int Urol Nephrol. 2007;39(4):1031-7 [17340210.001]
  • [Cites] Cell Tissue Res. 2008 Feb;331(2):401-12 [17965884.001]
  • [Cites] Biochem Soc Trans. 2008 Apr;36(Pt 2):141-7 [18363554.001]
  • [Cites] Genet Mol Res. 2008;7(2):295-304 [18551395.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Aug;67(2):153-71 [18342535.001]
  • [Cites] Mol Biosyst. 2008 Aug;4(8):835-50 [18633485.001]
  • [Cites] Trends Neurosci. 2008 Sep;31(9):487-94 [18684518.001]
  • [Cites] Virchows Arch. 2008 Sep;453(3):267-74 [18712413.001]
  • [Cites] Clin Neuropathol. 2008 Sep-Oct;27(5):334-45 [18808065.001]
  • [Cites] Surg Neurol. 2008 Nov;70(5):471-7; discussion 477 [18586307.001]
  • [Cites] Cell Commun Adhes. 2008 Nov;15(4):365-78 [18937087.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(5):489-92 [19051819.001]
  • [Cites] Cell Mol Life Sci. 2008 Nov;65(23):3756-88 [18726070.001]
  • [Cites] Genomics. 1995 Mar 20;26(2):281-9 [7601454.001]
  • [Cites] Neurosurgery. 1997 Jun;40(6):1269-77 [9179901.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):3-15 [15527101.001]
  • [Cites] Pathol Int. 2005 Jan;55(1):1-7 [15660696.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7951-7 [16258095.001]
  • (PMID = 20574529.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC2888586
  •  go-up   go-down


73. Rosenberg LA, Prayson RA, Lee J, Reddy C, Chao ST, Barnett GH, Vogelbaum MA, Suh JH: Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution. Int J Radiat Oncol Biol Phys; 2009 Jun 1;74(2):427-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution.
  • PURPOSE: To evaluate the outcomes for patients with Grade III meningiomas as defined by the 2007 World Health Organization standards.
  • METHODS AND MATERIALS: The slides from patients who had been treated at the Cleveland Clinic for malignant meningiomas were reviewed by a single neuropathologist.
  • The data from 13 patients treated between 1984 and 2006 satisfied the World Health Organization 2007 definition of Grade III meningioma.
  • CONCLUSION: This is one of the few studies reporting the outcomes for malignant meningioma patients according to recent definitions.
  • Our results are consistent with existing reports of the overall poor outcomes for atypical and malignant meningioma patients.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Meningioma / radiotherapy. Meningioma / surgery. Salvage Therapy / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19427553.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Tanaka A: Imaging diagnosis and fundamental knowledge of common brain tumors in adults. Radiat Med; 2006 Jul;24(6):482-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging diagnosis and fundamental knowledge of common brain tumors in adults.
  • The most common primary brain tumors in Japanese adults are meningiomas, gliomas, pituitary adenomas, and schwannomas, which together account for 84.0% of all primary brain tumors.
  • For instance, genetic analysis is important for differentiating oligodendroglial tumors from astrocytic tumors, and the gene mutation predicts response to chemotherapy for anaplastic oligodendrogliomas.
  • A differential diagnosis with knowledge of the above may have some advantages over diagnoses based on imaging findings alone.
  • [MeSH-major] Brain Neoplasms / diagnosis. Magnetic Resonance Imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Glioma / diagnosis. Humans. Image Processing, Computer-Assisted. Japan / epidemiology. Meningioma / diagnosis. Neurilemmoma / diagnosis. Pituitary Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Sep-Oct;14(5):1241-7 [8237710.001]
  • [Cites] Neuromolecular Med. 2003;3(1):41-52 [12665675.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Sep-Oct;11(5):935-8 [2120998.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):3972-82 [10566636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):65-73 [10924973.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Aug;22(7):1306-15 [11498419.001]
  • [Cites] Radiology. 1999 Nov;213(2):383-8 [10551216.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Mar;15(3):525-32 [8197952.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):78-81 [10585587.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):69-73 [9647174.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] J Neuroimaging. 1996 Apr;6(2):104-7 [8634482.001]
  • [Cites] Radiology. 1990 Aug;176(2):447-50 [2367659.001]
  • [Cites] Neuroradiology. 1997 Aug;39(8):593-8 [9272499.001]
  • [Cites] Surg Neurol. 2002 Dec;58(6):395-402; discussion 402 [12517619.001]
  • [Cites] Radiology. 1997 Apr;203(1):263-7 [9122405.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Mar;21(3):485-8 [10730639.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Sep-Oct;13(5):1279-91 [1414816.001]
  • [Cites] Radiology. 1994 Apr;191(1):41-51 [8134596.001]
  • [Cites] Cancer. 1975 Jul;36(1):216-20 [1203849.001]
  • [Cites] Nihon Igaku Hoshasen Gakkai Zasshi. 1998 Jun;58(7):349-52 [9711074.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Mar;18(3):551-4 [9090422.001]
  • [Cites] Surg Neurol. 1994 Jun;41(6):486-9 [8059328.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Jun-Jul;22(6):1081-8 [11415902.001]
  • [Cites] Radiology. 2002 Jul;224(1):177-83 [12091680.001]
  • [Cites] Radiology. 2003 Aug;228(2):533-8 [12819334.001]
  • [Cites] Jpn J Clin Oncol. 2001 Oct;31(10):510-3 [11696622.001]
  • (PMID = 16958433.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 31
  •  go-up   go-down


75. Smith JS, Lal A, Harmon-Smith M, Bollen AW, McDermott MW: Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma. J Neurosurg; 2007 Jun;106(6):1034-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma.
  • OBJECT: The clinical behavior of meningiomas is variable.
  • Because multiple growth factor receptors have been identified in these tumors, the authors sought to assess the capacity of the expression patterns of a subset of these receptors to stratify meningioma cases.
  • METHODS: Eighty-four meningiomas were analyzed, including 36 benign, 29 atypical, and 19 malignant lesions.
  • Immunoreactivity for EGFR was observed in 47% of benign, 48% of atypical, and 42% of malignant tumors.
  • Staining for BFGFR was identified in 89% of benign, 97% of atypical, and 95% of malignant lesions.
  • Mean MIB-I indices for benign, atypical, and malignant cases were 3.6 (range 0.5-15.3), 8.2 (range 1.5-23.1) and 18.3 (range 1.0-55.8), respectively.
  • Lack of EGFR immunoreactivity was identified as a strong predictor of shorter overall survival in patients with atypical meningioma (p = 0.003, log-rank test).
  • This association was not evident in cases of benign or malignant meningiomas.
  • CONCLUSIONS: There is a significant association between EGFR immunoreactivity and prolonged survival in patients with atypical meningioma.
  • Given the variable behavior of atypical meningiomas, EGFR assessment could improve existing strategies for patient stratification and treatment.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Receptor, Epidermal Growth Factor / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17564176.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-sis; 0 / Receptors, Fibroblast Growth Factor; 103107-01-3 / Fibroblast Growth Factor 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


76. Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW: Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry; 2008 May;79(5):574-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.
  • OBJECTIVES: To evaluate patient outcome and investigate the prognostic factors of high-grade meningiomas by adopting the 2000 World Health Organization (WHO) classification system.
  • METHODS: Between 1986 and 2004, 74 patients were diagnosed with high-grade meningioma: 33 with atypical and 41 with anaplastic meningioma.
  • RESULTS: Forty of 74 meningiomas were reclassified as atypical meningioma and 24 as anaplastic meningioma.
  • Overall and recurrence-free survivals were significantly longer in patients with atypical than in those with anaplastic meningioma: 142.5 versus 39.8 months and 138.5 versus 32.2 months, respectively (p<0.001).
  • In patients with atypical meningiomas, brain invasion and adjuvant radiotherapy were not associated with survival; however, in the brain invasion subgroup, adjuvant radiotherapy improved patients' survival.
  • In patients with anaplastic meningioma, the prognostic factors were brain invasion, adjuvant radiotherapy, malignant progression, p53 overexpression and extent of resection.
  • The p53 overexpression was the only factor associated with malignant progression (p = 0.009).
  • CONCLUSIONS: The 2000 WHO classification has identified the truly aggressive meningiomas better than did the previous criteria.
  • A precise meningioma grading system may help to avoid over-treatment of patients with an atypical meningioma as, once the tumour has "declared itself" by recurrence and histological features, it becomes a tumour that is poorly amenable to current therapies.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adult. Aged. Brain / pathology. Combined Modality Therapy. Cranial Irradiation. Disease Progression. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic / genetics. Humans. Ki-67 Antigen / genetics. Korea. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / classification. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome. Tumor Suppressor Protein p53 / genetics. World Health Organization

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17766430.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


77. Raza SM, Garzon-Muvdi T, Boaehene K, Olivi A, Gallia G, Lim M, Subramanian P, Quinones-Hinojosa A: The supraorbital craniotomy for access to the skull base and intraaxial lesions: a technique in evolution. Minim Invasive Neurosurg; 2010 Feb;53(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intra-axial pathology ranged from anaplastic astrocytoma to metastasis while extra-axial lesions included meningiomas and skull-based metastases.
  • [MeSH-minor] Adenoma / surgery. Astrocytoma / surgery. Breast Neoplasms / surgery. Craniopharyngioma / surgery. Esthetics. Eyebrows. Eyelids. Female. Follow-Up Studies. Frontal Lobe / surgery. Humans. Male. Meningeal Neoplasms / surgery. Meningioma / surgery. Middle Aged. Pituitary Neoplasms / surgery. Postoperative Complications / etiology. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 20376737.001).
  • [ISSN] 1439-2291
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


78. Vranic A, Popovic M, Cör A, Prestor B, Pizem J: Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: a study of 86 patients. Neurosurgery; 2010 Oct;67(4):1124-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: a study of 86 patients.
  • BACKGROUND: Since precise diagnostic criteria for atypical and malignant meningiomas (AMMs) were provided for the first time in the 2000 World Health Organization (WHO) criteria, there is only sparse information about possible prognostic factors in the group of AMMs.
  • METHODS: We analyzed 86 primary AMMs, 76 of which were atypical and 10 of which were malignant, diagnosed according to the 2000 WHO classification.
  • [MeSH-major] Brain / pathology. Meningeal Neoplasms. Meningioma. Mitotic Index. Neoplasm Recurrence, Local / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881577.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


79. Garcia-Conde M, Roldan-Delgado H, Martel-Barth-Hansen D, Manzano-Sanz C: Anaplastic transformation of an atypical intraventricular meningioma with metastases to the liver: case report. Neurocirugia (Astur); 2009 Dec;20(6):541-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic transformation of an atypical intraventricular meningioma with metastases to the liver: case report.
  • OBJECTIVE: Malignant intraventricular meningiomas are very rare.
  • We present herein the first case of a malignant intraventricular meningioma with extraneural metastases.
  • Histological examination demonstrated an atypical meningioma.
  • Histological examination showed anaplastic meningioma.
  • Biopsy was consistent with liver metastases of a malignant meningioma.
  • The patient died of acute liver failure seven months after initial diagnosis.
  • CONCLUSION: Malignant intraventricular meningiomas are prone to recur and develop metastases, mainly through the CSF.
  • Therefore, when systemic deterioration occurs in a patient with a malignant intraventricular meningioma, metastases to extraneural organs such as the liver must be ruled out.
  • [MeSH-major] Anaplasia / pathology. Liver Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19967319.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


80. Terzi A, Saglam EA, Barak A, Soylemezoglu F: The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays. Pathol Res Pract; 2008;204(5):305-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays.
  • Although histologic grading of meningiomas has prognostic and clinical implications, it is difficult in some cases to predict the outcome of patients.
  • There have been several efforts to evaluate the use of different immunohistochemical markers for predicting meningioma prognosis.
  • We analyzed the immunohistochemical expression of Ki-67, p53, p21, p16, and PTEN proteins in 130 meningiomas (64 benign, 39 atypical, and 27 malignant meningiomas) using tissue microarray.
  • There was a statistically significant correlation between the expression of Ki-67, p53, p21, p16, and the grade of meningiomas (p0.001).
  • In contrast, multivariate analysis revealed that only tumor grade is an independent factor for predicting meningioma recurrence.
  • We conclude that the Ki-67 and p53 labeling indices are useful additional tools in discriminating atypical from benign or anaplastic meningiomas, especially in histological borderline cases.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Immunohistochemistry. Ki-67 Antigen / analysis. Meningeal Neoplasms / chemistry. Meningioma / chemistry. Tissue Array Analysis. Tumor Suppressor Protein p53 / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18374497.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


81. Baia GS, Dinca EB, Ozawa T, Kimura ET, McDermott MW, James CD, VandenBerg SR, Lal A: An orthotopic skull base model of malignant meningioma. Brain Pathol; 2008 Apr;18(2):172-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An orthotopic skull base model of malignant meningioma.
  • Meningioma tumor growth involves the subarachnoid space that contains the cerebrospinal fluid.
  • Modeling tumor growth in this microenvironment has been associated with widespread leptomeningeal dissemination, which is uncharacteristic of human meningiomas.
  • We report the development and characterization of a reproducible orthotopic skull-base meningioma model in athymic mice using the IOMM-Lee cell line.
  • These tumors had histopathologic characteristics of anaplastic meningiomas including high cellularity, nuclear pleomorphism, cellular pattern loss, necrosis and conspicuous mitosis.
  • Similar to human meningiomas, considerable invasion of the dura and skull and some invasion of adjacent brain along perivascular tracts were observed.
  • The pattern of hypoxia was also similar to human malignant meningiomas.
  • Thus, we describe a malignant meningioma model system that will be useful for investigating the biology of meningiomas and for preclinical assessment of therapeutic agents.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Transplantation / methods. Skull Base Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18093250.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / 1R03NS054829-01; United States / NCI NIH HHS / CA / P50CA097257
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Tumor Suppressor Proteins; 147336-22-9 / Green Fluorescent Proteins; 298-93-1 / thiazolyl blue; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


82. Shah AB, Muzumdar GA, Chitale AR: Meningiomas: report of a hospital-based registry. Indian J Pathol Microbiol; 2005 Oct;48(4):468-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningiomas: report of a hospital-based registry.
  • This is a hospital-based epidemiologic study of meningiomas.
  • Of 1321 central nervous system tumours, meningiomas constituted 21% of the cases, being the second largest category of a single histologic type after astrocytomas.
  • Of the 267 meningiomas studied, 247 were intra-cranial (92.5%).
  • 261 (98%) meningiomas were histologically benign and 5 were malignant meningiomas (1.9%).
  • Of note was the fact, that out of 261 patients with benign meningiomas, 11 succumbed in the immediate post-operative period and in 8 of these cases, the tumour was located at the base of the skull.
  • [MeSH-major] Meningeal Neoplasms / epidemiology. Meningioma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366096.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


83. Strassner C, Buhl R, Mehdorn HM: Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years? Neurol Res; 2009 Jun;31(5):478-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years?
  • OBJECTIVE: Meningiomas are benign intracranial tumors growing from the arachnoid cap cells.
  • METHODS: Between 1991 and 2002, 463 patients with an intracranial meningioma were operated in the Department of Neurosurgery, University of Kiel, Kiel, Germany.
  • We compared the outcome of these patients after operation and the different methods of radiation therapy and chemotherapy with the data from Buhl (1994), who analysed 661 patients with intracranial meningioma who were operated on in the Department of Neurosurgery, University of Essen, Essen, Germany, between 1968 and 1988, to find out whether better methods of diagnosis like magnetic resonance imaging scans, magnetic resonance spectroscopy, post-operative radiation therapy and chemotherapy have an influence on the recurrence and outcome after surgical treatment.
  • Both studies underlined the preponderance of female patients for intracranial meningiomas.
  • The intracranial localization of the meningiomas was similar to the distribution of the histological subtypes and the rate of recurrence; only the malignant meningiomas showed a higher grade of recurrence in the last study.
  • The outcome of the patients after surgical removal was improving in the last years; the 30 day post-operative mortality after a primary operation on an intracranial meningioma decreased from 12.1 to 3%.
  • After removal of a recurrent meningioma, the mortality declined from 20 to 12.5%.
  • CONCLUSION: In the last 30 years, nothing important changed at the time of appearance of meningiomas, concerning the gender distribution and localisation as well as histological subtypes.
  • With better operating modalities and additional treatment with radiation and gamma knife, the mortality decreased significantly from 12 to 3% and the outcome of the patients is still improving, so that even elderly patients with intracranial meningioma can undergo surgical treatment with minor risks.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500450.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


84. Agar NY, Malcolm JG, Mohan V, Yang HW, Johnson MD, Tannenbaum A, Agar JN, Black PM: Imaging of meningioma progression by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Anal Chem; 2010 Apr 1;82(7):2621-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of meningioma progression by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
  • Often considered benign, meningiomas represent 32% of intracranial tumors with three grades of malignancy defined by the World Health Organization (WHO) histology based classification.
  • Malignant meningiomas are associated with less than 2 years median survival.
  • The inability to predict recurrence and progression of meningiomas induces significant anxiety for patients and limits physicians in implementing prophylactic treatment approaches.
  • Five recurrent and progressive meningiomas for which surgical specimens were available from the original and progressed grades were selected and tested against nonprogressive high-grade meningiomas, high-grade gliomas, and nontumor brain specimens.
  • A preliminary classifier based on the support vector machine showed the ability to distinguish meningioma image spectra from the nontumor brain and from gliomas, a different type of brain tumor, and to enable class imaging of surgical tissue.

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2001 Apr;7(4):493-6 [11283679.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18126-31 [18776051.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):981-7 [14871976.001]
  • [Cites] Anal Chem. 2004 Feb 15;76(4):1145-55 [14961749.001]
  • [Cites] J Proteome Res. 2004 Mar-Apr;3(2):245-52 [15113100.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1057-68 [15466373.001]
  • [Cites] Anal Chem. 1997 Dec 1;69(23):4751-60 [9406525.001]
  • [Cites] J Am Soc Mass Spectrom. 1999 Jan;10(1):67-71 [9888186.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9093-100 [15604278.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):394-401 [15677390.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7674-81 [16140934.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6550-7 [16166432.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1720-6 [16546995.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Anal Chem. 2007 Oct 1;79(19):7416-23 [17822313.001]
  • [Cites] J Cell Mol Med. 2008 Sep-Oct;12(5A):1535-47 [18266982.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):728-34 [12640680.001]
  • (PMID = 20196536.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / U41 RR019703; United States / NIBIB NIH HHS / EB / U54 EB005149-030003; United States / NIBIB NIH HHS / EB / U54 EB005149; United States / NCRR NIH HHS / RR / P41 RR-13218; United States / NCRR NIH HHS / RR / RR013218-108435; United States / NCRR NIH HHS / RR / P41 RR013218-108435; United States / NCRR NIH HHS / RR / P41 RR013218; United States / NIBIB NIH HHS / EB / EB005149-030003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS184740; NLM/ PMC2852177
  •  go-up   go-down


85. Mattei TA, Mattei JA, Ramina R, Aguiar PH, Plese JP, Marino Jr R: Edema and malignancy in meningiomas. Clinics (Sao Paulo); 2005 Jun;60(3):201-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Edema and malignancy in meningiomas.
  • PURPOSE: In recent years there have been many attempts to define a subset of aggressive malignant meningiomas based on histopathology and imaging technologies.
  • METHODS: The cases of 55 patients with meningiomas who underwent surgery at the Hospital das Clinicas (Fac Med Univ Sao Paulo) between September 1993 and September 1997 were reviewed.
  • Histological classification was: benign meningioma--43 cases; atypical meningiomas--11 cases; malignant meningioma--1 case.
  • CONCLUSIONS: These results suggest that the degree of edema as revealed by computer tomography and magnetic resonance imaging can be an important clinical predictive factor for the histological grade of the meningioma.
  • [MeSH-major] Brain Edema / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962080.001).
  • [ISSN] 1807-5932
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


86. Patel R, Win H, Desai S, Patel K, Matthews JA, Acevedo-Duncan M: Involvement of PKC-iota in glioma proliferation. Cell Prolif; 2008 Feb;41(1):122-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, in vivo, the status and function of PKC-iota in human normal brain tissue, gliomas, benign and malignant meningiomas as well as its in vitro status in proliferating and confluent glioma cells, remains unknown.
  • OBJECTIVES: The objectives of our research were to determine whether expression of PKC-iota is altered either in gliomas or in benign and malignant meningiomas, compared to normal brain.
  • MATERIALS AND METHODS: Western blot analyses for PKC-iota were performed on 12 normal brain biopsies, 15 benign meningiomas, three malignant meningiomas and three gliomas.
  • In comparison, PKC-iota was robustly present in the majority of the benign meningiomas.
  • Similarly, PKC-iota was abundant in all malignant meningiomas and gliomas.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18211289.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / RNA, Small Interfering; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / protein kinase C lambda
  •  go-up   go-down


87. Schittenhelm J, Mittelbronn M, Roser F, Tatagiba M, Mawrin C, Bornemann A: Patterns of SPARC expression and basement membrane intactness at the tumour-brain border of invasive meningiomas. Neuropathol Appl Neurobiol; 2006 Oct;32(5):525-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of SPARC expression and basement membrane intactness at the tumour-brain border of invasive meningiomas.
  • Brain invasive meningiomas are supposed to disrupt the pial-glial basement membrane.
  • In the present study we aimed at determining the relationship of basement membrane intactness and SPARC protein expression at the meningioma-brain border.
  • Sections of 51 brain-invasive meningiomas (31 meningothelial meningiomas WHO grade I, 11 atypical WHO grade II, and nine anaplastic WHO grade III tumours) were immunolabelled with antibodies against SPARC, epithelial membrane antigen (EMA), collagen IV and glial fibrillary acidic protein (GFAP).
  • Twenty-two non-invasive WHO grade I meningothelial meningiomas were included in the study for comparison.
  • At the tumour-brain border of invasive meningiomas, spindle-shaped tumour cells expressed SPARC.
  • In conclusion, the destruction of the basement membrane is correlated with meningioma malignancy grade whereas the expression of SPARC protein at the tumour-brain border is not.
  • Destruction of the basement membrane and appearance of SPARC+ spindle cells are not coincident during the course of brain invasion by meningiomas.
  • [MeSH-major] Basement Membrane / pathology. Brain / pathology. Brain Neoplasms / pathology. Meningioma / pathology. Osteonectin / biosynthesis. Osteonectin / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16972886.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Collagen Type IV; 0 / Glial Fibrillary Acidic Protein; 0 / Osteonectin
  •  go-up   go-down


88. Krayenbühl N, Pravdenkova S, Al-Mefty O: De novo versus transformed atypical and anaplastic meningiomas: comparisons of clinical course, cytogenetics, cytokinetics, and outcome. Neurosurgery; 2007 Sep;61(3):495-503; discussion 503-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo versus transformed atypical and anaplastic meningiomas: comparisons of clinical course, cytogenetics, cytokinetics, and outcome.
  • OBJECTIVE: The clinical course of atypical and anaplastic meningiomas is heterogeneous.
  • As malignant gliomas, aggressive meningiomas may arise de novo or transform from a benign tumor.
  • This study aims to compare differences in clinical behavior, cytogenetics, cytokinetics, receptor status, and outcome between de novo malignant meningiomas and meningiomas that progressed to malignancy.
  • METHODS: Data from 36 patients with atypical or anaplastic meningiomas were selected for retrospective analysis and divided into two subgroups:.
  • 1) de novo atypical or anaplastic tumors and 2) tumors that progressed from a lower grade.
  • For meningiomas with progression, we calculated the interval between initial diagnosis and tumor progression.
  • RESULTS: For atypical meningiomas, the subgroups had significant differences in status of progesterone receptors, proliferative indices, cytogenetics, and patients' outcome.
  • The anaplastic group had similar differences, but they did not reach statistical significance because of the small numbers.
  • These phenomena occurred mainly in patients with malignant transformation who had a worse outcome.
  • CONCLUSION: De novo malignant meningiomas and meningiomas with malignant transformation may represent distinct subgroups of atypical and anaplastic meningiomas.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Cytogenetic Analysis / methods. Meningioma / genetics. Meningioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17881961.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Tummalapalli P, Spomar D, Gondi CS, Olivero WC, Gujrati M, Dinh DH, Rao JS: RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. Int J Oncol; 2007 Nov;31(5):1039-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis.
  • Malignant meningiomas are highly aggressive and frequently recur after surgical resection of the tumor.
  • In the present study, we made an attempt to evaluate the roles of these proteases in the malignant meningioma tumor microenvironment and determined the effectiveness of using single or bicistronic siRNA constructs for cathepsin B and MMP-9, in both in vitro and in vivo models.
  • The migration and invasion of meningioma cells were decreased after treatment with single or bicistronic siRNA constructs for cathepsin B and MMP-9 compared to controls and vector controls.
  • Our study revealed that abrogation of cathepsin B and MMP-9 expression decreased the activation of major proteins involved in MAP kinase and PI3 kinase pathways indicating that targeting these proteases may hinder intracellular signaling and thus decrease cell survival and proliferation in malignant meningiomas.
  • Furthermore, these observations demonstrate that the simultaneous RNAi-mediated targeting of cathepsin B and MMP-9 has potential application for the treatment of human meningiomas.

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2006 Mar 1;20(5):543-56 [16481467.001]
  • [Cites] Int J Oncol. 2006 Mar;28(3):633-9 [16465367.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):716-28 [16469948.001]
  • [Cites] Oncol Rep. 2006 May;15(5):1321-6 [16596205.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2B):1589-94 [16619576.001]
  • [Cites] Exp Lung Res. 2006 Mar-Apr;32(3-4):69-79 [16754473.001]
  • [Cites] Bull Mem Acad R Med Belg. 2005;160(10-12):417-24; discussion 424-5 [16768246.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6699-707 [16818644.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 1;347(3):566-73 [16843436.001]
  • [Cites] Transplantation. 2006 Aug 15;82(3):340-7 [16906031.001]
  • [Cites] J Clin Invest. 2006 Aug;116(8):2132-2141 [16862213.001]
  • [Cites] Curr Med Chem. 2006;13(19):2309-27 [16918357.001]
  • [Cites] BMC Cancer. 2006;6:211 [16916471.001]
  • [Cites] Neurochem Res. 2006 Sep;31(9):1163-70 [16944316.001]
  • [Cites] Prostate. 2006 Nov 1;66(15):1631-40 [16927303.001]
  • [Cites] Mol Cell Biochem. 2006 Nov;292(1-2):189-95 [16733801.001]
  • [Cites] Gynecol Obstet Invest. 2006;62(4):229-35 [16837781.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):19-30 [16897429.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 7;1477(1-2):98-111 [10708852.001]
  • [Cites] Cancer. 2001 Mar 1;91(5):972-82 [11251949.001]
  • [Cites] Oncogene. 2001 Jun 21;20(28):3665-73 [11439329.001]
  • [Cites] Oncogene. 2001 Dec 6;20(56):8066-74 [11781819.001]
  • [Cites] Oncogene. 2002 Aug 15;21(36):5601-8 [12165859.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2894-901 [12231534.001]
  • [Cites] Biochem J. 2002 Oct 1;367(Pt 1):209-17 [12086583.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6318-22 [12414663.001]
  • [Cites] Chest. 2003 Feb;123(2):463-7 [12576367.001]
  • [Cites] Biol Chem. 2003 Mar;384(3):447-55 [12715895.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):271-86 [12785001.001]
  • [Cites] J Neurosci. 2003 Jun 15;23(12):4967-74 [12832519.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):316-23 [12845667.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):2767-72 [12926111.001]
  • [Cites] Acta Neurochir (Wien). 2003 Sep;145(9):777-81; discussion 781 [14505105.001]
  • [Cites] Eur Urol. 2003 Nov;44(5):560-6 [14572755.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):27-30 [14729603.001]
  • [Cites] Neoplasma. 2004;51(1):38-43 [15004658.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4681-9 [15122332.001]
  • [Cites] FASEB J. 2004 Jul;18(10):1123-5 [15132991.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):28880-8 [15128735.001]
  • [Cites] Cancer Res. 1991 Feb 15;51(4):1137-42 [1997157.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6553-60 [1384965.001]
  • [Cites] Anat Rec. 1993 Feb;235(2):233-40 [7678371.001]
  • [Cites] Biochim Biophys Acta. 1993 Jul 28;1178(1):55-62 [8329457.001]
  • [Cites] J Cell Sci. 1994 Feb;107 ( Pt 2):373-84 [8207069.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6027-31 [7954439.001]
  • [Cites] Clin Exp Metastasis. 1995 Jan;13(1):49-56 [7820956.001]
  • [Cites] Auris Nasus Larynx. 1995;22(1):43-8 [7677635.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5279-84 [8912869.001]
  • [Cites] Biol Chem. 1996 Nov;377(11):695-702 [8960370.001]
  • [Cites] Matrix Biol. 1998 Mar;16(9):575-84 [9569125.001]
  • [Cites] Hum Pathol. 1998 May;29(5):522-6 [9596278.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12410-5 [9770500.001]
  • [Cites] APMIS. 1999 Jan;107(1):28-37 [10190277.001]
  • [Cites] J Cell Physiol. 1999 Aug;180(2):271-84 [10395297.001]
  • [Cites] Clin Exp Metastasis. 1999 Mar;17(2):177-81 [10411111.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122(6):926-30 [15539385.001]
  • [Cites] Semin Cancer Biol. 2005 Apr;15(2):149-57 [15652460.001]
  • [Cites] Oncology. 2004;67(5-6):450-9 [15714002.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):287-97 [15781315.001]
  • [Cites] Cancer Lett. 2005 Jun 8;223(2):313-22 [15896466.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5158-66 [16033831.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):179-81 [16193389.001]
  • [Cites] Braz J Med Biol Res. 2005 Dec;38(12):1749-57 [16302089.001]
  • [Cites] Histol Histopathol. 2006 Jun;21(6):603-8 [16528670.001]
  • (PMID = 17912429.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS 057529; United States / NINDS NIH HHS / NS / NS047699-03; United States / NCI NIH HHS / CA / R01 CA075557-09; United States / NINDS NIH HHS / NS / R01 NS057529; United States / NCI NIH HHS / CA / CA 95088; United States / NINDS NIH HHS / NS / NS 47699; United States / NCI NIH HHS / CA / R01 CA116708-02; United States / NCI NIH HHS / CA / R01 CA075557; United States / NCI NIH HHS / CA / R01 CA095058-04; United States / NCI NIH HHS / CA / CA 75557; United States / NCI NIH HHS / CA / CA116708-02; United States / NCI NIH HHS / CA / CA 92393; United States / NINDS NIH HHS / NS / NS057529-01; United States / NINDS NIH HHS / NS / R01 NS057529-01; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / CA092393-04; United States / NCI NIH HHS / CA / R01 CA095058; United States / NINDS NIH HHS / NS / R01 NS047699-03; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA 116708; United States / NCI NIH HHS / CA / R01 CA092393-04; United States / NCI NIH HHS / CA / CA095058-04; United States / NCI NIH HHS / CA / CA075557-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.22.1 / Cathepsin B; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ NIHMS30797; NLM/ PMC2031211
  •  go-up   go-down


90. Lah TT, Nanni I, Trinkaus M, Metellus P, Dussert C, De Ridder L, Rajcević U, Blejec A, Martin PM: Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. J Neurosurg; 2010 May;112(5):940-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors.
  • OBJECT: The first aim of this study was to diagnose more aggressive and potentially recurrent meningiomas using an in vitro embryonic chick heart invasiveness assay in which lysosomal enzyme cathepsin B was used as the invasiveness marker.
  • The second aim was to confirm if cathepsin B and/or cathepsin L and their endogenous inhibitors were also prognostic parameters in the clinical study of 119 patients with meningioma.
  • METHODS: Primary meningioma cultured spheroids were "confronted" with embryonic chick heart spheroids in vitro, and cathepsin B was used as molecular marker to immunolabel the invasive tumor cells.
  • In vitro invasion assays of the malignant meningioma cells were used to assess the invasive potential related to the cysteine cathepsins.
  • As to the second aim, the possible association of cathepsin B along with selected molecular markers, cathepsin L, and endogenous cysteine protease inhibitors (stefins A and B and cystatin C) with meningioma malignancy was determined using enzyme-linked immunosorbent assays in tumor homogenates.
  • Univariate and multivariate analyses were used to compare these parameters with established biological markers of meningioma recurrence in 119 patients with meningiomas.
  • RESULTS: The more invasive tumors, which characteristically overgrew the normal tissue, were identified even within a group of histologically benign meningiomas.
  • Matrigel invasion of malignant meningioma cells was significantly altered by modulating cathepsin B activity and by stefin B silencing.
  • In the clinical samples of meningioma, the levels of cathepsins B and L, stefin B, and cystatin C were highest in the tumors of higher histological grades, whereas stefin A and progesterone receptor were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions.
  • CONCLUSIONS: The data indicate that the cysteine cathepsins and their inhibitors are involved in a process related to early meningioma recurrence, regardless of their histological classification.
  • Of note, the known tumor invasiveness marker cathepsin B, measured in whole-tumor homogenates, was not prognostic, in contrast to its endogenous inhibitor stefin B, which was highly significant and the only independent prognostic factor to predict meningioma relapse in multivariate analysis and reported herein for the first time.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Cysteine Proteinase Inhibitors / pharmacology. Cysteine Proteinase Inhibitors / therapeutic use. Lysosomes / drug effects. Meningioma / drug therapy. Meningioma / pathology


91. Fèvre-Montange M, Champier J, Durand A, Wierinckx A, Honnorat J, Guyotat J, Jouvet A: Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype. Int J Oncol; 2009 Dec;35(6):1395-407
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype.
  • Meningiomas, one of the largest subgroup of intracranial tumours are generally benign, but can progress to malignancy.
  • They are classified into the three World Health Organization grades: benign, atypical and anaplastic meningiomas.
  • We have performed a microarray transcriptomic study on 17 meningiomas of different malignancy using CodeLink Uniset Human Whole Genome Bioarrays to try to distinguish the different grades and histopathological subtypes.
  • Unsupervised hierarchical clustering classified the meningiomas into groups A, B and C, which corresponded to the three grades except for 3 benign meningiomas with higher proliferation indexes and/or recurrence, included in the atypical group.
  • In the benign tumours, we identified genes with signatures specific for fibroblastic meningiomas (FBLN1, Tenascin C and MMP2 encoding extracellular matrix proteins) and for meningothelial meningiomas (MLPH, DEFB1 and FAT3), suggesting different mechanisms involved in the tumorigenesis of these subtypes.
  • This microarray-based expression profiling study revealed candidate genes and pathways that may contribute to a better understanding of the recurrence of a benign meningioma.
  • Our results might make it possible to determine which benign meningiomas might recur despite complete resection, and will provide helpful information for neurosurgeons in the follow-up of the patients.
  • [MeSH-major] Gene Expression Profiling. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology


92. Gupta R, Suri V, Jain A, Sharma MC, Sarkar C, Singh MM, Joshi NP, Puri T, Julka PK: Anaplastic meningioma in an adolescent: a report of a rare case and brief review of literature. Childs Nerv Syst; 2009 Feb;25(2):241-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic meningioma in an adolescent: a report of a rare case and brief review of literature.
  • OBJECTIVE: Anaplastic meningioma is an uncommon neoplasm in childhood and adolescence.
  • Due to the rarity, treatment options for anaplastic meningioma in this age group are not clearly outlined.
  • Histopathological examination of the tumor showed features of an anaplastic meningioma.
  • CONCLUSION: Anaplastic meningioma is extremely rare in children.
  • Extensive sampling is required to recognize the meningothelial nature of the tumor and immunohistochemistry helps in making an accurate diagnosis in such cases.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Meningioma / diagnosis. Meningioma / therapy
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Mucin-1 / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Child Neurol. 2006 Jan;21(1):31-6 [16551450.001]
  • [Cites] Pediatr Neurosurg. 2005 Jan-Feb;41(1):1-7 [15886506.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2 Suppl Pediatrics):179-82 [14758946.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Expert Rev Neurother. 2006 Oct;6(10):1447-64 [17078786.001]
  • [Cites] Childs Brain. 1980;7(1):43-56 [7428495.001]
  • [Cites] J Neurosurg. 1996 May;84(5):733-6 [8622144.001]
  • [Cites] Childs Nerv Syst. 1986;2(3):160-1 [3779674.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):157-65 [16193387.001]
  • [Cites] Neurol Med Chir (Tokyo). 1978;18(1 Pt 1):119-27 [77488.001]
  • (PMID = 18769931.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mucin-1; 0 / Vimentin
  • [Number-of-references] 11
  •  go-up   go-down


93. Bozkurt SU, Ayan E, Bolukbasi F, Elmaci I, Pamir N, Sav A: Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. APMIS; 2009 Sep;117(9):651-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
  • Meningioma is a common neoplasm that constitutes almost 30% of all primary central nervous system tumors and is associated with inconsistent clinical outcomes.
  • The extracellular matrix proteins play a crucial role in meningioma cell biology and are important in tumor cell invasion and in progression to malignancy.
  • The aim of this study was to evaluate the expression of SPARC with proliferation index, p53 reactivity in WHO grade 1 (benign), grade 2 (atypical) and grade 3 (anaplastic) meningiomas and correlate with clinical features of the patients, including location of the tumor, recurrence of the tumor and survival of patients.
  • We studied 111 meningiomas, 69 being benign, 34 being atypical and eight being anaplastic meningiomas of various histological types.
  • Using immunohistochemical analysis, we evaluated the expression of SPARC, Ki-67 (MIB-1) and p53 in meningiomas.
  • A high immunohistochemical score (4-6) for SPARC was more frequent in atypical and in anaplastic meningiomas than in benign meningiomas (p < 0.01).
  • MIB-1 proliferation index showed significant association between tumor grades in meningiomas (p < 0.01).
  • The immunoreactivity of p53 protein and MIB-1 score were significantly higher in recurrent meningiomas than in non-recurrent meningiomas.
  • The high SPARC expression scores were predominantly identified in meningothelial, fibrous and chordoid meningiomas; low SPARC expression scores were mostly spotted in secretory and psammomatous meningiomas.
  • Evaluating SPARC expression might help assessing recurrence risk and survival estimation in meningiomas.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism. Osteonectin / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19703125.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Osteonectin; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


94. Panagopoulos AT, Lancellotti CL, Veiga JC, de Aguiar PH, Colquhoun A: Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol; 2008 Aug;89(1):73-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas.
  • Most meningiomas are benign tumours of arachnoidal origin, although a small number have high proliferative rates and invasive properties which complicate complete surgical resection and are associated with increased recurrence rates.
  • Few prognostic indicators exist for meningiomas and further research is necessary to identify factors that influence tumour invasion, oedema and recurrence.
  • Paraffin sections from 25 intracranial meningiomas were analysed for expression of the proteins vascular endothelial growth factor (VEGF), VEGF receptors Flt1 and Flk1, E-cadherin, metalloproteinases 2 and 9 (MMP2, MMP9), CD44, receptor for hyaluronic acid-mediated motility (RHAMM), hyaluronic acid (HA), CD45, cyclooxygenase 2 (COX2), brain fatty acid binding protein (BFABP), Ki67, and proliferating cell nuclear antigen (PCNA).
  • No correlations were found for MMP2, E-cadherin, or CD44 in meningiomas.
  • In conclusion Ki67, PCNA, MI, MVD, BFABP, and COX2 were significantly correlated with meningioma tumour grade and with each other.
  • These findings, by correlating both intracellular fatty acid transport and eicosanoid metabolism with tumour proliferation, as determined by Ki67 labelling and mitotic index, suggest fatty acids are involved in the progression of meningiomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / biosynthesis. Fatty Acids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neoplasm Proteins / biosynthesis. Neovascularization, Pathologic / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Acta Neuropathol. 1999 Sep;98(3):240-4 [10483780.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):529-38 [17016718.001]
  • [Cites] Neurosurg Focus. 2005 Nov 15;19(5):E9 [16398473.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):183-92; discussion 192-3 [12182416.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):508-17 [16235684.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4589-92 [11717317.001]
  • [Cites] Br J Neurosurg. 1998 Oct;12(5):414-8 [10070443.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):6-13 [14693827.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):235-45 [12510775.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Dec;32(6):674-8 [17083481.001]
  • [Cites] Neuroradiology. 1982;23 (4):207-9 [7121811.001]
  • [Cites] Cell Biol Int. 2006 Sep;30(9):704-13 [16829143.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):S98-102 [12902865.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Histopathology. 2006 Aug;49(2):178-87 [16879395.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 Feb;32(2):65-71 [1376862.001]
  • [Cites] Pathol Int. 2005 Jan;55(1):1-7 [15660696.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] BMC Cancer. 2006 Apr 19;6:97 [16623952.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] J Biochem Mol Biol. 2006 Sep 30;39(5):469-78 [17002866.001]
  • [Cites] J Cell Biol. 2006 Dec 18;175(6):1017-28 [17158951.001]
  • [Cites] Clinics (Sao Paulo). 2005 Jun;60(3):201-6 [15962080.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 6;330(2):489-97 [15796909.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):163-7 [9504862.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Br J Neurosurg. 1995;9(1):47-50 [7786426.001]
  • [Cites] Lung Cancer. 2006 Jul;53(1):91-6 [16697074.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Apr;30(2):118-25 [15043709.001]
  • [Cites] Trends Immunol. 2006 Mar;27(3):146-53 [16423560.001]
  • [Cites] J Histochem Cytochem. 1998 May;46(5):585-94 [9606106.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 Mar;27(3):460-8 [16788715.001]
  • [Cites] J Clin Neurosci. 2007 Apr;14(4):359-63 [17236775.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):29-37 [15015767.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1078-82 [12450029.001]
  • [Cites] Pathol Res Pract. 2006;202(5):365-72 [16563650.001]
  • [Cites] Childs Nerv Syst. 1995 Nov;11(11):661-3 [8608584.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):219-23 [15980972.001]
  • [Cites] Histopathology. 2006 Jun;48(7):836-45 [16722933.001]
  • [Cites] J Neurooncol. 2002 Nov;60(2):159-64 [12635663.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):19-30 [16078103.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Matrix Biol. 2007 Jan;26(1):58-68 [17055233.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10233-7 [17079438.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):936-44 [10091773.001]
  • [Cites] Stroke. 2006 Jun;37(6):1399-406 [16690896.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):483-8 [12478663.001]
  • [Cites] J Neurooncol. 2004 Dec;70(3):349-57 [15662977.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3962-5 [12124327.001]
  • [Cites] Clin Mol Pathol. 1996 Jun;49(3):M140-6 [16696062.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] J Appl Genet. 2006;47(1):39-48 [16424607.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1567-74 [10861283.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Epilepsy Res. 2000 Jan;38(1):45-52 [10604605.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):131-7 [16850103.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 18418552.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Eicosanoids; 0 / Fatty Acids; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


95. Haase D, Schmidl S, Ewald C, Kalff R, Huebner C, Firsching R, Keilhoff G, Evert M, Paulus W, Gutmann DH, Lal A, Mawrin C: Fatty acid synthase as a novel target for meningioma therapy. Neuro Oncol; 2010 Aug;12(8):844-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatty acid synthase as a novel target for meningioma therapy.
  • Similar to other hormone receptor-positive tumor types, meningiomas are progesterone receptor- and estrogen receptor-immunoreactive brain tumors.
  • To define the role of FAS in human meningioma growth control, we first analyzed the FAS expression using a tissue microarray containing 38 meningiomas and showed increased FAS expression in 70% of atypical WHO grade II and anaplastic WHO grade III meningiomas compared with 10% of benign WHO grade I tumors.
  • Second, we demonstrated that treatment with the FAS inhibitor, cerulenin (Cer), significantly decreased meningioma cell survival in vitro.
  • Fourth, we demonstrated that Cer treatment of mice bearing meningioma xenografts resulted in significantly reduced tumor volumes associated with increased meningioma cell death.
  • Collectively, our data suggest that the increased FAS expression in human meningiomas represents a novel therapeutic target for the treatment of unresectable or malignant meningioma.
  • [MeSH-major] Cerulenin / pharmacology. Fatty Acid Synthases / metabolism. Fatty Acid Synthesis Inhibitors / pharmacology. Meningeal Neoplasms / enzymology. Meningioma / enzymology

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 2000 May;48(5):613-22 [10769045.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3450-4 [10716717.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):153-7 [11205903.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1493-9 [11245456.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1626-35 [11920521.001]
  • [Cites] Exp Cell Res. 2003 Jan 15;282(2):132-7 [12531699.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7794-808 [14560023.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7330-7 [14612531.001]
  • [Cites] Oncol Rep. 2004 Aug;12(2):411-22 [15254710.001]
  • [Cites] Ann Neurol. 2004 Aug;56(2):295-8 [15293284.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36608-15 [15220355.001]
  • [Cites] J Biochem. 1989 May;105(5):751-5 [2666407.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2243-9 [2804914.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6379-83 [8022791.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1189-93 [8640795.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):45-51 [8986532.001]
  • [Cites] Neurology. 1997 Jul;49(1):267-70 [9222206.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4589-93 [9494573.001]
  • [Cites] Am J Physiol. 1999 Aug;277(2 Pt 1):L381-90 [10444533.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):99-108 [15543204.001]
  • [Cites] Oncogene. 2005 Jan 6;24(1):39-46 [15489885.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] J Pathol. 2005 Jun;206(2):214-9 [15880754.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4074-82 [15930342.001]
  • [Cites] Oncogene. 2005 May 19;24(22):3574-82 [15806173.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5070-5 [15958550.001]
  • [Cites] Clin Neuropathol. 2005 Jul-Aug;24(4):175-83 [16033134.001]
  • [Cites] Lab Invest. 2005 Sep;85(9):1163-71 [15965488.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):5977-80 [16778164.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):869-78 [16969344.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):735-45 [17234785.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):763-77 [17882277.001]
  • [Cites] Biomed Pharmacother. 2007 Oct;61(9):578-87 [17904792.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):314-22 [18172325.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • (PMID = 20511185.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acid Synthesis Inhibitors; 0 / RNA, Messenger; 17397-89-6 / Cerulenin; EC 2.3.1.85 / Fatty Acid Synthases
  • [Other-IDs] NLM/ PMC2940685
  •  go-up   go-down


96. Liu Y, Pang JC, Dong S, Mao B, Poon WS, Ng HK: Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol; 2005 Apr;36(4):416-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas.
  • The aim of this study was to investigate whether promoter hypermethylation of cancer-related genes is involved in the development and progression of meningiomas.
  • The methylation status at the promoter region of 10 cancer-related genes was examined by methylation-specific polymerase chain reaction in a cohort of 48 meningiomas including 16 benign, 19 atypical, and 13 anaplastic variants.
  • Our results showed that 50% (24/48) of meningiomas exhibited promoter hypermethylation in at least one of the genes but not in normal leptomeninges, indicating that aberrant hypermethylation is tumor-specific.
  • Treatment of IOMM-Lee meningioma cell line with 5-aza-2'-deoxycytidine restored expression of O 6 -methylguanine-DNA methyltransferase and death-associated protein kinase 1, providing evidence that promoter hypermethylation contributes to transcriptional silencing.
  • The frequencies of methylation of any single gene in benign, atypical, and malignant meningiomas were 6% (1/16), 74% (14/19), and 69% (9/13), respectively.
  • Of 48 tumors, 13 (27%) showed that concurrent hypermethylation of two or more genes studied were of atypical or anaplastic type.
  • Statistical analysis revealed that the incidence of promoter hypermethylation of any single gene, of multiple genes, or of glutathione S -transferase P1 was significantly associated with atypical and anaplastic meningiomas ( P < .0001, P = .004, and P = .004, respectively).
  • In conclusion, this study demonstrates that aberrant hypermethylation profile is associated with atypical and anaplastic meningiomas, suggesting that epigenetic change may be involved in malignant progression of meningiomas.
  • [MeSH-major] Azacitidine / analogs & derivatives. CpG Islands. DNA Methylation. Meningioma / genetics. Promoter Regions, Genetic

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15892004.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


97. Shinoura N, Takahashi M, Yamada R: Delineation of brain tumor margins using intraoperative sononavigation: implications for tumor resection. J Clin Ultrasound; 2006 May;34(4):177-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Sononavigation was performed on 12 brain tumors (7 metastatic brain tumors, 2 meningiomas, 1 anaplastic oligodendroglioma, 1 anaplastic pilocytic astrocytoma, and 1 anaplastic astrocytoma).
  • RESULTS: Three metastatic brain tumors and 1 meningioma were categorized as type 1.
  • Three metastatic brain tumors, 1 meningioma, and 1 anaplastic oligodendroglioma were categorized as type 2.
  • The anaplastic pilocytic astrocytoma, 1 metastatic brain tumor (which consisted mainly of necrotic tissue), and the anaplastic astrocytoma were categorized as type 3.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley Periodicals, Inc.
  • (PMID = 16615048.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


98. Qi ZG, Li YX, Wang Y, Geng DY, Li KC, Shen TZ, Chen XR: Lipid signal in evaluation of intracranial meningiomas. Chin Med J (Engl); 2008 Dec 5;121(23):2415-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid signal in evaluation of intracranial meningiomas.
  • BACKGROUND: Using magnetic resonance imaging, diagnosis of malignant meningioma from benign meningioma with atypical features is uncertain.
  • We evaluated the value of lipid signal in differentiating intracranial meningiomas.
  • RESULTS: Twenty-nine meningiomas were histologically benign (eleven meningothelial, thirteen fibrous, four transitional and one microcystic), three were atypical, and two were anaplastic.
  • Lipid signal was detected in ten cases: two anaplastic, three atypical, two fibrous and three meningothelial meningiomas.
  • With creatinine peak in the normal white matter chosen as internal standard, lipid/creatinine ratios of anaplastic, atypical and benign meningiomas were 0.844 +/- 0.027 (range from 0.725 to 0.994), 0.465 +/- 0.023 (range from 0.239 to 0.724), and 0.373 +/- 0.016 (range from 0.172 to 0.571) respectively.
  • Highly significant differences were noted between anaplastic and the other two subtypes.
  • Patchy necrosis was observed in anaplastic meningioma, while focal necrosis was noted in atypical meningioma with HE stain.
  • KP-1 stain demonstrated histocytes containing lipids in the necrotic region of anaplastic and atypical meningioma.
  • CONCLUSION: The lipid signal at 1.3 ppm is a useful marker in evaluating the malignancy of intracranial meningiomas, especially in the differential diagnosis of anaplastic meningioma.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102960.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


99. Miyatake S, Tamura Y, Kawabata S, Iida K, Kuroiwa T, Ono K: Boron neutron capture therapy for malignant tumors related to meningiomas. Neurosurgery; 2007 Jul;61(1):82-90; discussion 90-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neutron capture therapy for malignant tumors related to meningiomas.
  • OBJECTIVE: Malignant meningiomas, similar to glioblastomas, are difficult tumors to control.
  • We tried to control malignant tumors related to meningiomas by boron neutron capture therapy (BNCT).
  • METHODS: Since June 2005, we applied BNCT with 13 rounds of neutron irradiation to seven cases of malignant tumors related to meningiomas.
  • Three were anaplastic meningiomas, two were papillary meningiomas, one was an atypical meningioma, and one was a sarcoma transformed from a meningioma with cervical lymph node metastasis.
  • The atypical meningioma case showed a tumor-to-healthy brain ratio of 2.0.
  • Two of the three anaplastic meningiomas showed a complete response, and all six patients available for follow-up imaging showed radiographic improvements.
  • In this patient, a huge atypical meningioma arose from the falcotentorial junction and extended to the bilateral occipital lobes and brainstem; visual problems worsened after repetitive BNCT, with an increase in peritumoral edema.
  • CONCLUSION: Malignant meningiomas seem to be good candidates for BNCT.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621022.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


100. Okuducu AF, Zils U, Michaelis SA, Michaelides S, von Deimling A: Ets-1 is up-regulated together with its target gene products matrix metalloproteinase-2 and matrix metalloproteinase-9 in atypical and anaplastic meningiomas. Histopathology; 2006 Jun;48(7):836-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ets-1 is up-regulated together with its target gene products matrix metalloproteinase-2 and matrix metalloproteinase-9 in atypical and anaplastic meningiomas.
  • Little is known about the regulation of MMPs in meningioma development and prognosis.
  • The aim of this study was to determine the relationship between the expression of Ets-1, MMP-2 and -9 and the malignant potential of meningiomas.
  • METHODS AND RESULTS: Seventy-four meningiomas of different histological grades were investigated immunohistochemically.
  • Up-regulation of Ets-1, MMP-2 and MMP-9 expression was observed in atypical and anaplastic meningiomas.
  • Invasive meningiomas showed increased immunohistochemical expression of these proteins compared with non-invasive meningiomas.
  • CONCLUSIONS: Ets-1 may be involved in the transcriptional regulation of MMP-2 and MMP-9 as well as in the invasive process in meningiomas.
  • Evaluation of these expressions might be of prognostic value for meningiomas.
  • [MeSH-major] Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Meningeal Neoplasms / pathology. Meningioma / pathology. Proto-Oncogene Protein c-ets-1 / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16722933.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Protein c-ets-1; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down






Advertisement